Drug Name

Drug Name
Generic Name : metoprolol , metoprolol succinate , metoprolol tartrate

Brand Name: Apo-Metoprolol (CAN), Betaloc (CAN), Lopressor, Novo-metoprol (CAN), Nu-Metop (CAN)
,Toprol-XL ,Lopressor Injection

Classification: Beta1-selective adrenergic blocker, Antihypertensive

Pregnancy Category C

Dosage & Route

Available forms : Tablets50, 100 mg; ER tablets25, 50, 100, 200 mg; injection1 mg/mL

ADULTS
Hypertension: Initially, 100 mg/day PO in single or divided doses; gradually increase dosage at
weekly intervals. Usual maintenance dose is 100450 mg/day.
Angina pectoris: Initially, 100 mg/day PO in two divided doses; may be increased gradually,
effective range 100400 mg/day.
MI, early treatment: Three IV bolus doses of 5 mg each at 2-min intervals with careful monitoring.
If these are tolerated, give 50 mg PO 15 min after the last IV dose and q 6 hr for 48 hr.
Thereafter, give a maintenance dosage of 100 mg PO bid. Reduce initial PO doses to 25 mg, or
discontinue in patients who do not tolerate the IV doses.
MI, late treatment: 100 mg PO bid as soon as possible after infarct, continuing for at least 3 mo
and possibly for 13 yr.
ER tablets
Hypertension: 25100 mg/day PO as one dose; may increase at weekly intervals to a maximum of
400 mg/day..
Angina: 100 mg/day PO as one dose.
CHF: 12.525 mg/day Toprol-XL for 2 wk; may then be increased by 25 mg every 2 wk to a
maximum of 200 mg.
PEDIATRIC PATIENTS
Safety and efficacy not established.

Therapeutic actions
Metoprolol selectively inhibits -adrenergic receptors but has little or no effect on 2-receptors
except in high doses. It has no membrane-stabilising nor intrinsic sympathomimetic activity.

Indications
Hypertension, alone or with other drugs, especially diuretics
Immediate-release tablets and injection: Prevention of reinfarction in MI patients who are
hemodynamically stable or within 310 days of the acute MI
Long-term treatment of angina pectoris
Toprol-XL only: Treatment of stable, symptomatic CHF of ischemic, hypertensive, or
cardiomyopathic origin

Adverse effects
Bradycardia, hypotension, arterial insufficiency, chest pain, CHF, edema, palpitation, syncope,
gangrene; dizziness, fatigue, depression, confusion, headache, insomnia, short-term memory
loss, nightmares, somnolence; pruritus, rash, increased psoriasis, reversible alopecia; sexual
dysfunction/impotence, Peyronie's disease; diarrhoea, constipation, flatulence, GI pain,
heartburn, nausea, xerostomia; agranulocytosis (rare); musculoskeletal pain; blurred vision, dry
eyes, oculomucocutaneous syndrome; tinnitus; dyspnea, bronchospasm, wheezing, rhinitis; cold
extremities.
Potentially Fatal: Heart failure, heart block, bronchospasm.

Contraindications
2nd or 3rd degree AV block; sick sinus syndrome; decompensated heart failure; clinically relevant
sinus bradycardia. Severe peripheral arterial circulatory disorders. Cardiogenic shock. Asthma.
Phaeochromocytoma (without -blockade), systolic BP <100 mmHg. Metabolic acidosis.
Pregnancy (2nd and 3rd trimesters).

Nursing considerations

Assessment
History: Sinus bradycardia (HR < 45 beats/min), second- or third-degree heart block (PR interval
> 0.24 sec), cardiogenic shock, CHF, systolic BP < 100 mm Hg; diabetes or thyrotoxicosis;
asthma or COPD; lactation, pregnancy
Physical: Weight, skin condition, neurologic status, P, BP, ECG, respiratory status, renal and
thyroid function tests, blood and urine glucose
Interventions
WARNING: Do not discontinue drug abruptly after long-term therapy (hypersensitivity to
catecholamines may have developed, causing exacerbation of angina, MI, and ventricular
arrhythmias). Taper drug gradually over 2 wk with monitoring.
Ensure that patient swallows the ER tablets whole; do not cut, crush, or chew. Toprol XL tablets
may be divided at the score; divided tablets should be swallowed whole, not crushed or chewed.
Consult physician about withdrawing drug if patient is to undergo surgery (controversial).
Give oral drug with food to facilitate absorption.
Provide continual cardiac monitoring for patients receiving IV metoprolol.
Teaching points
Do not stop taking this drug unless instructed to do so by a health care provider.
Swallow the extended-release tablets whole; do not cut, crush, or chew them. If using Toprol XL,
you can divide the tablets at the score; divided tablets must be swallowed whole, not crushed or
chewed.
You may experience these side effects: Dizziness, drowsiness, light-headedness, blurred vision
(avoid driving or dangerous activities); nausea, loss of appetite (eat frequent small meals);
nightmares, depression (discuss change of medication); sexual impotence.
Report difficulty breathing, night cough, swelling of extremities, slow pulse, confusion, depression,
rash, fever, sore throat.

Drug Name

Generic Name: amiodarone hydrochloride

Brand Name: Cordarone, Pacerone

Classification: Antiarrhythmic, Adrenergic blocker (not used as sympatholytic drug)

Pregnancy Category D

Dosages
Careful patient assessment and evaluation with continual monitoring of cardiac response are
necessary for titrating the dosage. Therapy should begin in the hospital with continual monitoring
and emergency equipment on standby. The following is a guide to usual dosage.
ADULTS

Oral
Loading dose: 8001,600 mg/day PO in divided doses, for 13 wk; reduce dose to 600800
mg/day in divided doses for 1 mo; if rhythm is stable, reduce dose to 400 mg/day in one to two
divided doses for maintenance dose. Adjust to the lowest possible dose to limit side effects.
IV
1,000 mg IV over 24 hr150 mg loading dose over 10 min, followed by 360 mg over 6 hr at rate
of 1 mg/min. For maintenance infusion, 540 mg at 0.5 mg/min over 18 hr. May be continued up to
96 hr or until rhythm is stable. Switch to oral form as soon as possible.
PEDIATRIC PATIENTS

Therapeutic actions
Type III antiarrhythmic: Acts directly on cardiac cell membrane; prolongs repolarization and
refractory period; increases ventricular fibrillation threshold; acts on peripheral smooth muscle to
decrease peripheral resistance

Indications
Only for treatment of the following documented life-threatening recurrent ventricular arrhythmias
that do not respond to other antiarrhythmics or when alternative agents are not tolerated:
Recurrent ventricular fibrillation, recurrent hemodynamically unstable ventricular tachycardia.
Serious and even fatal toxicity has been reported with this drug; use alternative agents first; very
closely monitor patient receiving this drug
Unlabeled uses: Treatment of refractory sustained or paroxysmal atrial fibrillation and paroxysmal
supraventricular tachycardia; treatment of symptomatic atrial flutter

Adverse effects
CNS: Malaise, fatigue, dizziness, tremors, ataxia, paresthesias, lack of coordination
CV: Cardiac arrhythmias, CHF, cardiac arrest, hypotension
EENT: Corneal microdeposits (photophobia, dry eyes, halos, blurred vision); ophthalmic
abnormalities including permanent blindness
Endocrine: Hypothyroidism or hyperthyroidism
GI: Nausea, vomiting, anorexia, constipation, abnormal LFTs, hepatotoxicity
Respiratory: Pulmonary toxicitypneumonitis, infiltrates (shortness of breath, cough, rales,
wheezes)
Other: Photosensitivity, angioedema

Contraindications
Contraindicated with hypersensitivity to amiodarone, sinus node dysfunction, heart block, severe
bradycardia, hypokalemia, lactation.
Use cautiously with thyroid dysfunction, pregnancy.


CLINICAL ALERT!
Name confusion has occurred with amrinone (name has now been changed to inamrinone, but
confusion may still occur); use caution.
Assessment
History: Hypersensitivity to amiodarone, sinus node dysfunction, heart block, severe bradycardia,
hypokalemia, lactation, thyroid dysfunction, pregnancy
Physical: Skin color, lesions; reflexes, gait, eye examination; P, BP, auscultation, continuous
ECG monitoring; R, adventitious sounds, baseline chest X-ray; liver evaluation; LFTs, serum
electrolytes, T4, and T3
Interventions
WARNING: Reserve use for life-threatening arrhythmias; serious toxicity, including arrhythmias,
pulmonary toxicity can occur.
Monitor cardiac rhythm continuously.
Monitor for an extended period when dosage adjustments are made.
WARNING: Monitor for safe and effective serum levels (0.52.5 mcg/mL).
WARNING: Doses of digoxin, quinidine, procainamide, phenytoin, and warfarin may need to be
reduced one-third to one-half when amiodarone is started.
Give drug with meals to decrease GI problems.
Arrange for ophthalmologic examinations; reevaluate at any sign of optic neuropathy.
Arrange for periodic chest X-ray to evaluate pulmonary status (every 36 mo).
Arrange for regular periodic blood tests for liver enzymes, thyroid hormone levels.
Teaching points
Drug dosage will be changed in relation to response of arrhythmias; you will need to be
hospitalized during initiation of drug therapy; you will be closely monitored when dosage is
changed.
Have regular medical follow-up, monitoring of cardiac rhythm, chest X-ray, eye examination,
blood tests.
You may experience these side effects: Changes in vision (halos, dry eyes, sensitivity to light;
wear sunglasses, monitor light exposure); nausea, vomiting, loss of appetite (take with meals; eat
frequent small meals); sensitivity to the sun (use a sunscreen or protective clothing when
outdoors); constipation (a laxative may be ordered); tremors, twitching, dizziness, loss of
coordination (do not drive, operate dangerous machinery, or undertake tasks that require
coordination until drug effects stabilize and your body adjusts to it).
Report unusual bleeding or bruising; fever, chills; intolerance to heat or cold; shortness of breath,
difficulty breathing, cough; swelling of ankles or fingers; palpitations; difficulty with vision.

Drug Name

Generic Name : furosemide

Brand Name: Apo-Furosemide (CAN), Furosemide Special (CAN), Lasix

Classification: Loop diuretic


Dosage & Route

Available forms :Tablets20, 40, 80 mg; oral solution10 mg/mL, 40 mg/5 mL; injection10 mg/mL

ADULTS
Edema: Initially, 2080 mg/day PO as a single dose. If needed, a second dose may be given in
68 hr. If response is unsatisfactory, dose may be increased in 20- to 40-mg increments at 6- to
8-hr intervals. Up to 600 mg/day may be given. Intermittent dosage schedule (24 consecutive
days/wk) is preferred for maintenance, or 2040 mg IM or IV (slow IV injection over 12 min).
May increase dose in increments of 20 mg in 2 hr. High-dose therapy should be given as infusion
at rate not exceeding 4 mg/min.
Acute pulmonary edema: 40 mg IV over 12 min. May be increased to 80 mg IV given over 12
min if response is unsatisfactory after 1 hr.
Hypertension: 40 mg bid PO. If needed, additional antihypertensive agents may be added.

PEDIATRIC PATIENTS

Avoid use in premature infants: stimulates prostaglandin E2 synthesis and may increase incidence of
patent ductus arteriosus and complicate respiratory distress syndrome.
Edema: Initially, 2 mg/kg/day PO. If needed, increase by 12 mg/kg in 68 hr. Do not exceed 6
mg/kg. Adjust maintenance dose to lowest effective level.
Pulmonary edema: 1 mg/kg IV or IM. May increase by 1 mg/kg in 2 hr until the desired effect is
seen. Do not exceed 6 mg/kg.

PATIENTS WITH RENAL IMPAIRMENT
Up to 4 g/day has been tolerated. IV bolus injection should not exceed 1 g/day given over 30 min.

Therapeutic actions
Furosemide inhibits reabsorption of Na and chloride mainly in the medullary portion of the
ascending Loop of Henle. Excretion of potassium and ammonia is also increased while uric acid
excretion is reduced. It increases plasma-renin levels and secondary hyperaldosteronism may
result. Furosemide reduces BP in hypertensives as well as in normotensives. It also reduces
pulmonary oedema before diuresis has set in.

Indications
Oral, IV: Edema associated with CHF, cirrhosis, renal disease
IV: Acute pulmonary edema
Oral: Hypertension

Adverse effects
Fluid and electrolyte imbalance. Rashes, photosensitivity, nausea, diarrhoea, blurred vision,
dizziness, headache, hypotension. Bone marrow depression (rare), hepatic dysfunction.
Hyperglycaemia, glycosuria, ototoxicity.
Potentially Fatal: Rarely, sudden death and cardiac arrest. Hypokalaemia and magnesium
depletion can cause cardiac arrhythmias.

Contraindications
Severe sodium and water depletion, hypersensitivity to sulphonamides and furosemide,
hypokalaemia, hyponatraemia, precomatose states associated with liver cirrhosis, anuria or renal
failure. Addison's disease.


CLINICAL ALERT!
Name confusion has occurred between furosemide and torsemide; use extreme caution.
Assessment
History: Allergy to furosemide, sulfonamides, tartrazine; electrolyte depletion anuria, severe renal
failure; hepatic coma; SLE; gout; diabetes mellitus; lactation, pregnancy
Physical: Skin color, lesions, edema; orientation, reflexes, hearing; pulses, baseline ECG, BP,
orthostatic BP, perfusion; R, pattern, adventitious sounds; liver evaluation, bowel sounds; urinary
output patterns; CBC, serum electrolytes (including calcium), blood sugar, LFTs, renal function
tests, uric acid, urinalysis, weight
Interventions
BLACK BOX WARNING: Profound diuresis with water and electrolyte depletion can occur; careful
medical supervision is required.
Administer with food or milk to prevent GI upset.
Reduce dosage if given with other antihypertensives; readjust dosage gradually as BP responds.
Give early in the day so that increased urination will not disturb sleep.
Avoid IV use if oral use is at all possible.
WARNING: Do not mix parenteral solution with highly acidic solutions with pH below 3.5.
Do not expose to light, may discolor tablets or solution; do not use discolored drug or solutions.
Discard diluted solution after 24 hr.
Refrigerate oral solution.
Measure and record weight to monitor fluid changes.
Arrange to monitor serum electrolytes, hydration, liver and renal function.
Arrange for potassium-rich diet or supplemental potassium as needed.
Teaching points
Record intermittent therapy on a calendar or dated envelopes. When possible, take the drug early
so increased urination will not disturb sleep. Take with food or meals to prevent GI upset.
Weigh yourself on a regular basis, at the same time and in the same clothing, and record the
weight on your calendar.
Blood glucose levels may become temporarily elevated in patients with diabetes after starting this
drug.
You may experience these side effects: Increased volume and frequency of urination; dizziness,
feeling faint on arising, drowsiness (avoid rapid position changes; hazardous activities, like
driving; and consumption of alcohol); sensitivity to sunlight (use sunglasses, wear protective
clothing, or use a sunscreen); increased thirst (suck on sugarless lozenges; use frequent mouth
care); loss of body potassium (a potassium-rich diet or potassium supplement will be needed).
Report loss or gain of more than 3 pounds in 1 day, swelling in your ankles or fingers, unusual
bleeding or bruising, dizziness, trembling, numbness, fatigue, muscle weakness or cramps.
Drug Name

Generic Name : diazepam

Brand Name:Apo-Diazepam (CAN), Diastat, Diazemuls (CAN), Diazepam Intensol, Valium

Classification: Benzodiazepine, Anxiolytic, Antiepileptic, Skeletal muscle relaxant (centrally acting)

Controlled Substance C-IV

Dosage & Route

Dosages
Individualize dosage; increase dosage cautiously to avoid adverse effects.
ADULTS

Oral
Anxiety disorders, skeletal muscle spasm, seizure disorders: 210 mg bidqid.
Alcohol withdrawal: 10 mg tidqid first 24 hr; reduce to 5 mg tidqid, as needed.
Oral sustained-release
Anxiety disorders: 1530 mg/day.
Alcohol withdrawal: 30 mg first 24 hr; reduce to 15 mg/day as needed.

Rectal
0.2 mg/kg PR; treat no more than one episode q 5 days. May give a second dose in 412 hr.
Parenteral

Usual dose is 220 mg IM or IV. Larger doses may be required for some indications (tetanus). Injection
may be repeated in 1 hr.
Anxiety: 210 mg IM or IV; repeat in 34 hr if necessary.
Alcohol withdrawal: 10 mg IM or IV initially, then 510 mg in 34 hr if necessary.
Endoscopic procedures: 10 mg or less, up to 20 mg IV just before procedure or 510 mg IM 30
min prior to procedure. Reduce or omit dosage of opioids.
Muscle spasm: 510 mg IM or IV initially, then 510 mg in 34 hr if necessary.
Status epilepticus: 510 mg, preferably by slow IV. May repeat q 510 min up to total dose of 30
mg. If necessary, repeat therapy in 24 hr; other drugs are preferable for long-term control.
Preoperative: 10 mg IM.
Cardioversion: 515 mg IV 510 min before procedure.

PEDIATRIC PATIENTS

Oral
> 6 mo: 12.5 mg PO tidqid initially. Gradually increase as needed and tolerated. Can be given
rectally if needed.
Rectal
< 2 yr: Not recommended.
25 yr: 0.5 mg/kg.
611 yr: 0.3 mg/kg.
>12 yr: Use adult dose; may give a second dose in 412 hr.
Parenteral

Maximum dose of 0.25 mg/kg IV administered over 3 min; may repeat after 1530 min. If no relief of
symptoms after three doses, adjunctive therapy is recommended.
Tetanus (> 1 mo): 12 mg IM or IV slowly q 34 hr as necessary.
Tetanus (> 5 yr): 510 mg q 34 hr.
Status epilepticus (> 1 mo< 5 yr): 0.20.5 mg slowly IV q 25 min up to a maximum of 5 mg.
Status epilepticus (> 5 yr): 1 mg IV q 25 min up to a maximum of 10 mg; repeat in 24 hr if
necessary.

GERIATRIC PATIENTS OR PATIENTS WITH DEBILITATING DISEASE

22.5 mg PO dailybid or 25 mg parenteral initially; reduce rectal dose. Gradually increase as needed
and tolerated; use cautiously.

Therapeutic actions
Diazepam is a long-acting benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle
relaxant and amnestic properties. It increases neuronal membrane permeability to chloride ions
by binding to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron within
the CNS and enhancing the GABA inhibitory effects resulting in hyperpolarisation and
stabilisation.

Indications
Management of anxiety disorders or for short-term relief of symptoms of anxiety
Acute alcohol withdrawal; may be useful in symptomatic relief of acute agitation, tremor, delirium
tremens, hallucinosis
Muscle relaxant: Adjunct for relief of reflex skeletal muscle spasm due to local pathology
(inflammation of muscles or joints) or secondary to trauma; spasticity caused by upper
motoneuron disorders (cerebral palsy and paraplegia); athetosis, stiff-man syndrome
Parenteral: Treatment of tetanus
Antiepileptic: Adjunct in status epilepticus and severe recurrent convulsive seizures (parenteral);
adjunct in seizure disorders (oral)
Preoperative (parenteral): Relief of anxiety and tension and to lessen recall in patients prior to
surgical procedures, cardioversion, and endoscopic procedures
Rectal: Management of selected, refractory patients with epilepsy who require intermittent use to
control bouts of increased seizure activity
Unlabeled use: Treatment of panic attacks

Adverse effects
Psychological and physical dependence with withdrawal syndrome; fatigue, drowsiness, sedation,
ataxia, vertigo, confusion, depression, GI disturbances, changes in salivation, amnesia, jaundice,
paradoxical excitation, elevated liver enzyme values; muscle weakness, visual disturbances,
headache, slurring of speech and dysarthria; mental changes; incontinence, constipation;
hypotension, tachycardia; changes in libido; pain and thrombophloebitis at Inj site (IV).
Potentially Fatal: Respiratory and CNS depression; coma.

Contraindications
Hypersensitivity; preexisting CNS depression or coma, respiratory depression; acute pulmonary
insufficiency or sleep apnoea; severe hepatic impairment; acute narrow angle glaucoma; children
< 6 mth; pregnancy and lactation.


Assessment
History: Hypersensitivity to benzodiazepines; psychoses, acute narrow-angle glaucoma, shock,
coma, acute alcoholic intoxication; elderly or debilitated patients; impaired liver or renal function;
pregnancy, lactation
Physical: Weight; skin color, lesions; orientation, affect, reflexes, sensory nerve function,
ophthalmologic examination; P, BP; R, adventitious sounds; bowel sounds, normal output, liver
evaluation; normal output; LFTs, renal function tests, CBC

Interventions
WARNING: Do not administer intra-arterially; may produce arteriospasm, gangrene.
Change from IV therapy to oral therapy as soon as possible.
Do not use small veins (dorsum of hand or wrist) for IV injection.
Reduce dose of opioid analgesics with IV diazepam; dose should be reduced by at least one-third
or eliminated.
Carefully monitor P, BP, respiration during IV administration.
WARNING: Maintain patients receiving parenteral benzodiazepines in bed for 3 hr; do not permit
ambulatory patients to operate a vehicle following an injection.
Monitor EEG in patients treated for status epilepticus; seizures may recur after initial control,
presumably because of short duration of drug effect.
Monitor liver and renal function, CBC during long-term therapy.
Taper dosage gradually after long-term therapy, especially in epileptic patients.
Arrange for epileptic patients to wear medical alert ID indicating that they are epileptics taking this
medication.
Discuss risk of fetal abnormalities with patients desiring to become pregnant.
Teaching points
Take this drug exactly as prescribed. Do not stop taking this drug (long-term therapy, antiepileptic
therapy) without consulting your health care provider.
Caregiver should learn to assess seizures, administer rectal form, and monitor patient.
Use of barrier contraceptives is advised while using this drug; if you become or wish to become
pregnant, consult with your health care provider.
It is advisable to wear a medical alert ID indicating your diagnosis and treatment (as antiepileptic).
You may experience these side effects: Drowsiness, dizziness (may lessen; avoid driving or
engaging in other dangerous activities); GI upset (take drug with food); dreams, difficulty
concentrating, fatigue, nervousness, crying (reversible).
Report severe dizziness, weakness, drowsiness that persists, rash or skin lesions, palpitations,
swelling of the ankles, visual or hearing disturbances, difficulty voiding.
Drug Name

Generic Name : digoxin

Brand Name: Digitek, Lanoxicaps, Lanoxin

Classification: Cardiac glycoside, Cardiotonic


Dosage & Route
Patient response is quite variable. Evaluate patient carefully to determine the appropriate dose.
ADULTS
Loading dose, 0.751.25 mg PO or 0.1250.25 mg IV. Maintenance dose, 0.1250.25 mg/day
PO.
Lanoxicaps capsules
Loading dose, 0.40.6 mg PO. Maintenance dose, 0.1 0.3 mg/day PO.
PEDIATRIC PATIENTS

Loading dose:
Oral (mcg/kg) IV (mcg/kg)
Premature 2030 1525
Neonate 2535 2030
124 mo 3560 3050
25 yr 3040 2535
510 yr 2035 1530
> 10 yr 1015 812
Maintenance dose, 20%30% of loading dose in divided daily doses. Usually 0.1250.5 mg/day PO;
20%30% for premature babies.

GERIATRIC PATIENTS WITH IMPAIRED RENAL FUNCTION
Creatinine Clearance
(mL/min)
Dose
1025 0.125 mg/day
2649 0.1875 mg/day
5079 0.25 mg/day

Therapeutic actions
Digoxin is a cardiac glycoside which has positive inotropic activity characterized by an increase in
the force of myocardial contraction. It also reduces the conductivity of the heart through the
atrioventricular (AV) node. Digoxin also exerts direct action on vascular smooth muscle and
indirect effects mediated primarily by the autonomic nervous system and an increase in vagal
activity.

Indications
CHF
Atrial fibrillation

Adverse effects
Extra beats, anorexia, nausea and vomiting. Diarrhoea in elderly, confusion, dizziness,
drowsiness, restlessness, nervousness, agitation and amnesia, visual disturbances,
gynaecomastia, local irritation (IM/SC inj), rapid IV admin may lead to vasocostriction and
transient hypertension.
Potentially Fatal: Cardiac arrhythmias in combination with heart block.

Contraindications
Digitalis toxicity, ventricular tachycardia/fibrillation, obstructive cardiomyopathy. Arrhythmias due
to accessory pathways (e.g. Wolff-Parkinson-White syndrome).


Assessment
History: Allergy to digitalis preparations, ventricular tachycardia, ventricular fibrillation, heart
block, sick sinus syndrome, IHSS, acute MI, renal insufficiency, decreased K+, decreased Mg2+
increased Ca2+, pregnancy, lactation
Physical: Weight; orientation, affect, reflexes, vision; P, BP, baseline ECG, cardiac auscultation,
peripheral pulses, peripheral perfusion, edema; R, adventitious sounds; abdominal percussion,
bowel sounds, liver evaluation; urinary output; electrolyte levels, LFTs, renal function tests
Interventions
WARNING: Monitor apical pulse for 1 min before administering; hold dose if pulse < 60 in adult or
< 90 in infant; retake pulse in 1 hr. If adult pulse remains < 60 or infant < 90, hold drug and notify
prescriber. Note any change from baseline rhythm or rate.
Take care to differentiate Lanoxicaps from Lanoxin; dosage is very different
Check dosage and preparation carefully.
Avoid IM injections, which may be very painful.
Follow diluting instructions carefully, and use diluted solution promptly.
Avoid giving with meals; this will delay absorption.
Have emergency equipment ready; have K+ salts, lidocaine, phenytoin, atropine, and cardiac
monitor readily available in case toxicity develops.
WARNING: Monitor for therapeutic drug levels: 0.52 ng/mL.
Teaching points
Do not stop taking this drug without notifying your health care provider.
Take pulse at the same time each day, and record it on a calendar (normal pulse for you is___;
call your health care provider if your pulse rate falls below ____.)
Weigh yourself every other day with the same clothing and at the same time. Record this on the
calendar.
Do not start taking any prescription or over-the-counter products without talking to your health
care provider. Some combinations may increase the risk of digoxin toxicity and may put you at
risk of adverse reactions.
Wear or carry a medical alert tag stating that you are on this drug.
Have regular medical checkups, which may include blood tests, to evaluate the effects and
dosage of this drug.
Report unusually slow pulse, irregular pulse, rapid weight gain, loss of appetite, nausea, diarrhea,
vomiting, blurred or "yellow" vision, unusual tiredness and weakness, swelling of the ankles, legs
or fingers, difficulty breathing.
DRUG NAME

Generic Name : diphenhydramine hydrochloride

Brand Name:
Oral: Allerdryl (CAN), AllerMax Caplets, Banophen, Banophen Allergy, Benadryl Allergy, Diphen
AF, Diphenhist, Diphenhist Captabs, Genahist, Siladryl, Silphen Cough
Oral prescription preparations: Benadryl, Tusstat
Parenteral preparations: Benadryl
Classification: Antihistamine, Anti-motion sickness drug, Sedative-hypnotic, Antiparkinsonian, Cough
suppressant

Pregnancy Category B

DOSAGE & ROUTE

ADULTS

Oral
2550 mg q 48 hr PO.
Motion sickness: Give full dose prophylactically 30 min before exposure to motion, and repeat
before meals and at bedtime.
Nighttime sleep aid: 2550 mg PO at bedtime.
Cough suppression: 25 mg q 4 hr PO, not to exceed 150 mg in 24 hr.
Parenteral
1050 mg IV or deep IM or up to 100 mg if required. Maximum daily dose is 400 mg.
PEDIATRIC PATIENTS > 10 KG OR 20 LB

Oral
12.525 mg tidqid PO or 5 mg/kg/day PO or 150 mg/m2 per day PO. Maximum daily dose 300
mg.
Motion sickness: Give full dose prophylactically 30 min before exposure to motion and repeat
before meals and at bedtime.
Cough suppression:
o 26 yr: 6.25 mg q 4 hr, not to exceed 25 mg in 24 hr.
o 612 yr: 12.5 mg q 4 hr PO, not to exceed 75 mg in 24 hr.
Parenteral
5 mg/kg/day or 150 mg/m2 per day IV or by deep IM injection. Maximum daily dose is 300 mg
divided into four doses.
GERIATRIC PATIENTS
More likely to cause dizziness, sedation, syncope, toxic confusional states, and hypotension in
elderly patients; use with caution.

THERAPEUTIC ACTIONS
Diphenhydramine blocks histamine H1-receptors on effector cells of the GI tract, blood vessels
and respiratory tract. It also causes sedation and has some anticholinergic action.

INDICATIONS
Relief of symptoms associated with perennial and seasonal allergic rhinitis; vasomotor rhinitis;
allergic conjunctivitis; mild, uncomplicated urticaria and angioedema; amelioration of allergic
reactions to blood or plasma; dermatographism; adjunctive therapy in anaphylactic reactions
Active and prophylactic treatment of motion sickness
Nighttime sleep aid
Parkinsonism (including drug-induced parkinsonism and extrapyramidal reactions), in the elderly
intolerant of more potent drugs, for milder forms of the disorder in other age groups, and in
combination with centrally acting anticholinergic antiparkinsonian drugs
Syrup formulation: Suppression of cough due to colds or allergy

ADVERSE EFFECTS
CNS depression, dizziness, headache, sedation; paradoxical stimulation in children; dryness of
mouth, thickened respiratory secretion, blurring of vision, urinary retention; GI disturbances; blood
dyscrasias.

CONTRAINDICATIONS
Hypersensitivity ; neonates, lactation.

NURSING CONSIDERATIONS

Assessment
History: Allergy to any antihistamines, narrow-angle glaucoma, stenosing peptic ulcer,
symptomatic prostatic hypertrophy, asthmatic attack, bladder neck obstruction, pyloroduodenal
obstruction, third trimester of pregnancy, lactation
Physical: Skin color, lesions, texture; orientation, reflexes, affect; vision examination; P, BP; R,
adventitious sounds; bowel sounds; prostate palpation; CBC with differential

Interventions
Administer with food if GI upset occurs.
Administer syrup form if patient is unable to take tablets.
Monitor patient response, and arrange for adjustment of dosage to lowest possible effective dose.

Teaching points
Take as prescribed; avoid excessive dosage.
Take with food if GI upset occurs.
Avoid alcohol; serious sedation could occur.
These side effects may occur: Dizziness, sedation, drowsiness (use caution driving or performing
tasks requiring alertness); epigastric distress, diarrhea or constipation (take drug with meals); dry
mouth (use frequent mouth care, suck sugarless lozenges); thickening of bronchial secretions,
dryness of nasal mucosa (use a humidifier).
Report difficulty breathing, hallucinations, tremors, loss of coordination, unusual bleeding or
bruising, visual disturbances, irregular heartbeat.
Drug Name

Generic Name : albuterol sulfate

Brand Name: AccuNeb, Novo-Salmol (CAN), Proventil, Proventil HFA, Salbutamol (CAN), Ventodisk
(CAN), Ventolin HFA

Classification: Sympathomimetic, Beta2-selective adrenergic agonist, Bronchodilator, Antasthmatic


Dosages

ADULTS

Oral
Initially, 2 or 4 mg (12 tsp syrup) tidqid PO; may cautiously increase dosage if necessary to 4
or 8 mg qid, not to exceed 32 mg/day.
Inhalation
Each actuation of aerosol dispenser delivers 90 mcg albuterol; 2 inhalations q 46 hr; some
patients may require only 1 inhalation q 4 hr; more frequent administration or larger number of
inhalations not recommended.
o Prevention of exercise-induced bronchospasm: 2 inhalations 15 min prior to exercise.
Solution for inhalation
2.5 mg tid to qid by nebulization.
Inhalation capsules
One 200 mcg capsule q 46 hr up to two 200 mcg capsules q 46 hr.
o Prevention of exercise-induced asthma: One 200 mcg capsule inhaled 15 min before
exercise.
PEDIATRIC PATIENTS

Oral, tablets
612 yr: 2 mg tidqid. Do not exceed 24 mg/day.
> 12 yr: Use adult dosage.
Oral, syrup
< 2 yr: Safety and efficacy not established.
26 yr: Initially 0.1 mg/kg tid, not to exceed 2 mg (1 tsp) tid; if necessary, cautiously increase
stepwise to 0.2 mg/kg tid. Do not exceed 4 mg (2 tsp) tid.
614 yr: 2 mg (1 tsp) tidqid; if necessary, cautiously increase dosage. Do not exceed 24 mg/day
in divided doses.
14 yr: Use adult dosage.
Inhalation
212 yr: For child 1015 kg, use 1.25 mg; for child > 15 kg, use 2.5 mg.
12 yr: Use adult dosage.
Solution for inhalation
1015 kg: 1.25 mg bid or tid by nebulization.
15 kg: 2.5 mg bid or tid by nebulization.
Inhalation capsules
> 4 yr: One 200 mcg capsule inhaled q 46 hr.
o Prevention of exercise-induced asthma: One 200 mcg capsule inhaled 15 min before
exercise.

Therapeutic actions
In low doses, acts relatively selectively at beta2-adrenergic receptors to cause bronchodilation
and vasodilation; at higher doses, beta2 selectivity is lost, and the drug acts at beta2 receptors to
cause typical sympathomimetic cardiac effects.

Indications
Relief and prevention of bronchospasm in patients with reversible obstructive airway disease
Inhalation: Treatment of acute attacks of bronchospasm
Prevention of exercise-induced bronchospasm
Unlabeled use: Adjunct in treating serious hyperkalemia in dialysis patients; seems to lower
potassium concentrations when inhaled by patients on hemodialysis

Adverse effects
CNS: Restlessness, apprehension, anxiety, fear, CNS stimulation, hyperkinesia, insomnia,
tremor, drowsiness, irritability, weakness, vertigo, headache
CV: Cardiac arrhythmias, tachycardia, palpitations, PVCs (rare), anginal pain
Dermatologic: Sweating, pallor, flushing
GI: Nausea, vomiting, heartburn, unusual or bad taste in mouth
GU: Increased incidence of leiomyomas of uterus when given in higher than human doses in
preclinical studies
Respiratory: Respiratory difficulties, pulmonary edema, coughing, bronchospasm, paradoxical
airway resistance with repeated, excessive use of inhalation preparations

Contraindications and cautions
Contraindicated with hypersensitivity to albuterol; tachyarrhythmias, tachycardia caused by
digitalis intoxication; general anesthesia with halogenated hydrocarbons or cyclopropane (these
sensitize the myocardium to catecholamines); unstable vasomotor system disorders;
hypertension; coronary insufficiency, CAD; history of CVA; COPD patients with degenerative
heart disease.
Use cautiously with diabetes mellitus (large IV doses can aggravate diabetes and ketoacidosis);
hyperthyroidism; history of seizure disorders; psychoneurotic individuals; labor and delivery (oral
use has delayed second stage of labor; parenteral use of beta2-adrenergic agonists can
accelerate fetal heart beat and cause hypoglycemia, hypokalemia, pulmonary edema in the
mother and hypoglycemia in the neonate); lactation; the elderly (more sensitive to CNS effects).


Assessment
History: Hypersensitivity to albuterol; tachyarrhythmias, tachycardia caused by digitalis
intoxication; general anesthesia with halogenated hydrocarbons or cyclopropane; unstable
vasomotor system disorders; hypertension; coronary insufficiency, CAD; history of CVA; COPD
patients who have developed degenerative heart disease; diabetes mellitus; hyperthyroidism;
history of seizure disorders; psychoneurotic individuals; lactation
Physical: Weight; skin color, T, turgor; orientation, reflexes, affect; P, BP; R, adventitious sounds;
blood and urine glucose, serum electrolytes, thyroid function tests, ECG
Interventions
Use minimal doses for minimal periods; drug tolerance can occur with prolonged use.
Maintain a beta-adrenergic blocker (cardioselective beta-blocker, such as atenolol, should be
used with respiratory distress) on standby in case cardiac arrhythmias occur.
Prepare solution for inhalation by diluting 0.5 mL 0.5% solution with 2.5 mL normal saline; deliver
over 515 min by nebulization.
Do not exceed recommended dosage; administer pressurized inhalation drug forms during
second half of inspiration, because the airways are open wider and the aerosol distribution is
more extensive.
Teaching points
Do not exceed recommended dosage; adverse effects or loss of effectiveness may result. Read
the instructions that come with respiratory inhalant.
You may experience these side effects: Dizziness, drowsiness, fatigue, headache (use caution if
driving or performing tasks that require alertness); nausea, vomiting, change in taste (eat frequent
small meals); rapid heart rate, anxiety, sweating, flushing, insomnia.
Report chest pain, dizziness, insomnia, weakness, tremors or irregular heart beat, difficulty
breathing, productive cough, failure to respond to usual dosage.
Drug Name

Generic Name: aspirin

Brand Name:Apo-ASA (CAN), Aspergum, Bayer, Easprin, Ecotrin, Empirin, Entrophen (CAN), Genprin,
Halfprin 81, 1/2 Halfprin, Heartline, Norwich, Novasen (CAN), PMS-ASA (CAN), ZORprin, Alka-Seltzer,
Ascriptin, Asprimox, Bufferin, Buffex, Magnaprin

Classification: Antipyretic, Analgesic (nonopioid), Anti-inflammatory, Antirheumatic, Antiplatelet,
Salicylate, NSAID


Dosage & Route
Available in oral and suppository forms. Also available as chewable tablets, gum; enteric coated,
SR, and buffered preparations (SR aspirin is not recommended for antipyresis, short-term
analgesia, or children < 12 yr.)
ADULTS
Minor aches and pains: 325650 mg q 4 hr.
Arthritis and rheumatic conditions: 3.26 g/day in divided doses.
Acute rheumatic fever: 58 g/day; modify to maintain serum salicylate level of 1530 mg/dL.
TIAs in men:1,300 mg/day in divided doses (650 mg bid or 325 mg qid).
MI prophylaxis: 75325 mg/day.
PEDIATRIC PATIENTS
Analgesic and antipyretic: 65 mg/kg per 24 hr in four to six divided doses, not to exceed 3.6
g/day. Dosage recommendations by age:
Age (yr) Dosage(mg q 4 hr)
23 162
45 243
68 324
910 405
11 486
12 648
Juvenile rheumatoid arthritis: 60110 mg/kg per 24 hr in divided doses at 6- to 8-hr intervals.
Maintain a serum level of 150300 mcg/mL.
Acute rheumatic fever: Initially, 100 mg/kg/day, then decrease to 75 mg/kg/day for 46 wk.
Therapeutic serum salicylate level is 150300 mg/dL.
Kawasaki disease: 80180 mg/kg/day; very high doses may be needed during acute febrile
period; after fever resolves, dosage may be adjusted to 10 mg/kg/day.

Therapeutic actions
Analgesic and antirheumatic effects are attributable to aspirin's ability to inhibit the synthesis of
prostaglandins, important mediators of inflammation. Antipyretic effects are not fully understood,
but aspirin probably acts in the thermoregulatory center of the hypothalamus to block effects of
endogenous pyrogen by inhibiting synthesis of the prostaglandin intermediary. Inhibition of
platelet aggregation is attributable to the inhibition of platelet synthesis of thromboxane A2, a
potent vasoconstrictor and inducer of platelet aggregation. This effect occurs at low doses and
lasts for the life of the platelet (8 days). Higher doses inhibit the synthesis of prostacyclin, a potent
vasodilator and inhibitor of platelet aggregation.

Indications
Mild to moderate pain
Fever
Inflammatory conditionsrheumatic fever, rheumatoid arthritis, osteoarthritis
Reduction of risk of recurrent TIAs or stroke in males with history of TIA due to fibrin platelet
emboli
Reduction of risk of death or nonfatal MI in patients with history of infarction or unstable angina
pectoris
MI prophylaxis
Unlabeled use: Prophylaxis against cataract formation with long-term use

Adverse effects
Acute aspirin toxicity: Respiratory alkalosis, hyperpnea, tachypnea, hemorrhage, excitement,
confusion, asterixis, pulmonary edema, seizures, tetany, metabolic acidosis, fever, coma, CV
collapse, renal and respiratory failure (dose related, 2025 g in adults, 4 g in children)
Aspirin intolerance: Exacerbation of bronchospasm, rhinitis (with nasal polyps, asthma, rhinitis)
GI: Nausea, dyspepsia, heartburn, epigastric discomfort, anorexia, hepatotoxicity
Hematologic: Occult blood loss, hemostatic defects
Hypersensitivity: Anaphylactoid reactions to anaphylactic shock
Salicylism: Dizziness, tinnitus, difficulty hearing, nausea, vomiting, diarrhea, mental confusion,
lassitude (dose related)

Contraindications
Contraindicated with allergy to salicylates or NSAIDs (more common with nasal polyps, asthma,
chronic urticaria); allergy to tartrazine (cross-sensitivity to aspirin is common); hemophilia,
bleeding ulcers, hemorrhagic states, blood coagulation defects, hypoprothrombinemia, vitamin K
deficiency (increased risk of bleeding)
Use cautiously with impaired renal function; chickenpox, influenza (risk of Reye's syndrome in
children and teenagers); children with fever accompanied by dehydration; surgery scheduled
within 1 wk; pregnancy (maternal anemia, antepartal and postpartal hemorrhage, prolonged
gestation, and prolonged labor have been reported; readily crosses the placenta; possibly
teratogenic; maternal ingestion of aspirin during late pregnancy has been associated with the
following adverse fetal effects: low birth weight, increased intracranial hemorrhage, stillbirths,
neonatal death); lactation.


Assessment
History: Allergy to salicylates or NSAIDs; allergy to tartrazine; hemophilia, bleeding ulcers,
hemorrhagic states, blood coagulation defects, hypoprothrombinemia, vitamin K deficiency;
impaired hepatic function; impaired renal function; chickenpox, influenza; children with fever
accompanied by dehydration; surgery scheduled within 1 wk; pregnancy; lactation
Physical: Skin color, lesions; T; eighth cranial nerve function, orientation, reflexes, affect; P, BP,
perfusion; R, adventitious sounds; liver evaluation, bowel sounds; CBC, clotting times, urinalysis,
stool guaiac, LFTs, renal function tests
Interventions
BLACK BOX WARNING: Do not use in children and teenagers to treat chickenpox or flu
symptoms without review for Reyes syndrome, a rare but fatal disorder.
Give drug with food or after meals if GI upset occurs.
Give drug with full glass of water to reduce risk of tablet or capsule lodging in the esophagus.
Do not crush, and ensure that patient does not chew SR preparations.
Do not use aspirin that has a strong vinegar-like odor.
WARNING: Institute emergency procedures if overdose occurs: Gastric lavage, induction of
emesis, activated charcoal, supportive therapy.
Teaching points
Take extra precautions to keep this drug out of the reach of children; this drug can be very
dangerous for children.
Use the drug only as suggested; avoid overdose. Avoid the use of other over-the-counter drugs
while taking this drug. Many of these drugs contain aspirin, and serious overdose can occur.
Take the drug with food or after meals if GI upset occurs.
Do not cut, crush, or chew sustained-release products.
Over-the-counter aspirins are equivalent. Price does not reflect effectiveness.
You may experience these side effects: Nausea, GI upset, heartburn (take drug with food); easy
bruising, gum bleeding (related to aspirin's effects on blood clotting).
Report ringing in the ears; dizziness, confusion; abdominal pain; rapid or difficult breathing;
nausea, vomiting, bloody stools.
Drug Name

Generic Name : nitroglycerin

Brand Name:
Intravenous: Generic
Spray: Nitrolingual Pumpspray
Sublingual: Gen-Nitroglycerin (CAN), NitroQuick, Nitrostat
Sustained-release: Nitro-Time
Topical: Nitro-Bid
Transdermal: Deponit, Minitran, Nitrek, Nitro-Dur, Transderm-Nitro
Translingual: Nitrolingual
Transmucosal: Nitrogard
Classification: Antianginal, Nitrate


Dosage & Route

Available forms : Injection0.5, 5 mg/mL; injection solution25, 50, 100, 200 mg; sublingual tablets
0.3, 0.4, 0.6 mg; translingual spray0.4 mg/spray; transmucosal tablets1, 2, 3 mg; transmucosal SR
tablets1, 2, 2.5, 3, 5 mg; oral SR capsules2.5, 6.5, 9 mg; transdermal0.1, 0.2, 0.3, 0.4, 0.6, 0.8
mg/hr; topical ointment2%

ADULTS

IV
Initial dose, 5 mcg/min delivered through an infusion pump. Increase by 5-mcg/min increments
every 35 min as needed. If no response at 20 mcg/min, increase increments to 1020 mcg/min.
Once a partial BP response is obtained, reduce dose and lengthen dosage intervals; continually
monitor response and titrate carefully.
Sublingual
Acute attack: Dissolve 1 tablet under tongue or in buccal pouch at first sign of anginal attack;
repeat every 5 min until relief is obtained. Do not take more than 3 tablets/15 min. If pain
continues or increases, patient should call physician or go to hospital.
Prophylaxis: Use 510 min before activities that might precipitate an attack.
SR (oral)
Initial dose, 2.59 mg q 12 hr. Increase to q 8 hr as needed and tolerated. Doses as high as 26
mg given qid have been used.
Topical
Initial dose, one-half inch q 8 hr. Increase by one-half inch to achieve desired results. Usual dose
is 12 inches q 8 hr; up to 45 inches q 4 hr have been used. 1 inch = 15 mg nitroglycerin.
Transdermal
Apply one patch each day. Adjust to higher doses by using patches that deliver more drug or by
applying more than one patch. Apply patch to arm; remove at bedtime.
Translingual
Spray preparation delivers 0.4 mg/metered dose. At onset of attack, spray one to two metered
doses into oral mucosa; no more than three doses/15 min should be used. If pain persists, seek
medical attention. May be used prophylactically 510 min before activity that might precipitate an
attack.
Transmucosal
1 mg q 35 hr during waking hours. Place tablet between lip and gum above incisors, or between
cheek and gum.
PEDIATRIC PATIENTS

Therapeutic actions
Relaxes vascular smooth muscle with a resultant decrease in venous return and decrease in
arterial BP, which reduces left ventricular workload and decreases myocardial oxygen
consumption.

Indications
Sublingual, translingual preparations: Acute angina
Oral SR, sublingual, topical, transdermal, translingual, transmucosal preparations: Prophylaxis of
angina
IV: Angina unresponsive to recommended doses of organic nitrates or beta-blockers
IV: Perioperative hypertension
IV: CHF associated with acute MI
IV: To produce controlled hypertension during surgery
Unlabeled uses: Reduction of cardiac workload in acute MI and in CHF (sublingual, topical);
adjunctive treatment of Raynaud's disease (topical)

Adverse effects
CNS: Headache, apprehension, restlessness, weakness, vertigo, dizziness, faintness
CV: Tachycardia, retrosternal discomfort, palpitations, hypotension, syncope, collapse, orthostatic
hypotension, angina
Dermatologic: Rash, exfoliative dermatitis, cutaneous vasodilation with flushing, pallor,
perspiration, cold sweat, contact dermatitistransdermal preparations, topical allergic
reactionstopical nitroglycerin ointment
GI: Nausea, vomiting, incontinence of urine and feces, abdominal pain
Local: Local burning sensation at the point of dissolution (sublingual)
Other: Ethanol intoxication with high-dose IV use (alcohol in diluent)

Contraindications
Contraindicated with allergy to nitrates, severe anemia, early MI, head trauma, cerebral
hemorrhage, hypertrophic cardiomyopathy, pregnancy, lactation.
Use cautiously with hepatic or renal disease, hypotension or hypovolemia, increased intracranial
pressure, constrictive pericarditis, pericardial tamponade, low ventricular filling pressure or low
PCWP.


CLINICAL ALERT!
Name confusion has occurred between NitroBid (nitrogylcerin) and Nicotral (nicotine); between
nitroglycerin and nitroprusside; use caution.
Assessment
History: Allergy to nitrates, severe anemia, early MI, head trauma, cerebral hemorrhage,
hypertrophic cardiomyopathy, hepatic or renal disease, hypotension or hypovolemia, increased
intracranial pressure, constrictive pericarditis, pericardial tamponade, low ventricular filling
pressure or low PCWP, pregnancy, lactation
Physical: Skin color, T, lesions; orientation, reflexes, affect; P, BP, orthostatic BP, baseline ECG,
peripheral perfusion; R, adventitious sounds; liver evaluation, normal output; LFTs, renal function
tests (IV); CBC, Hgb
Interventions
Give sublingual preparations under the tongue or in the buccal pouch. Encourage patient not to
swallow. Ask patient if the tablet "fizzles" or burns. Always check the expiration date on the bottle;
store at room temperature, protected from light. Discard unused drug 6 mo after bottle is opened
(conventional tablets); stabilized tablets (Nitrostat) are less subject to loss of potency.
Give sustained-release preparations with water; warn the patient not to chew the tablets or
capsules; do not crush these preparations.
Administer topical ointment by applying the ointment over a 6 6 inch area in a thin, uniform
layer using the applicator. Cover area with plastic wrap held in place by adhesive tape. Rotate
sites of application to decrease the chance of inflammation and sensitization; close tube tightly
when finished.
Administer transdermal systems to skin site free of hair and not subject to much movement.
Shave areas that have a lot of hair. Do not apply to distal extremities. Change sites slightly to
decrease the chance of local irritation and sensitization. Remove transdermal system before
attempting defibrillation or cardioversion. Remove old system before applying a new one.
Administer transmucosal tablets by placing them between the lip and gum above the incisors or
between the cheek and gum. Encourage patient not to swallow and not to chew the tablet.
Administer the translingual spray directly onto the oral mucosa; preparation is not to be inhaled.
WARNING: Arrange to withdraw drug gradually. 46 wk is the recommended withdrawal period
for the transdermal preparations.
Teaching points
Place sublingual tablets under your tongue or in your cheek; do not chew or swallow the tablet;
the tablet should burn or "fizzle" under the tongue. Take the nitroglycerin before chest pain
begins, when you anticipate that your activities or situation may precipitate an attack. You may
repeat your dose every 5 minutes for a total of three tablets. If the pain is not relieved, go to an
emergency room. Do not buy large quantities; this drug does not store well. Keep the drug in a
dark, dry place, in a dark-colored glass bottle with a tight lid; do not combine with other drugs.
Do not chew or crush the timed-release preparations; take on an empty stomach.
Spread a thin layer of topical ointment on the skin using the applicator. Do not rub or massage
the area. Cover with plastic wrap held in place with adhesive tape. Wash your hands after
application. Keep the tube tightly closed. Rotate the sites frequently to prevent local irritation.
To use transdermal systems, you may need to shave an area for application. Apply to a slightly
different area each day. Remove the old system before you apply a new one. Use care if
changing brands; each system has a different concentration.
Place transmucosal tablets between the lip and gum or between the gum and cheek. Do not
chew; try not to swallow.
Spray translingual spray directly onto oral mucous membranes; do not inhale. Use 510 min
before activities that you anticipate will precipitate an attack.
You may experience these side effects: Dizziness, light-headedness (may be transient; change
positions slowly); headache (lie down in a cool environment and rest; over-the-counter
preparations may not help); flushing of the neck or face (transient).
Report blurred vision, persistent or severe headache, rash, more frequent or more severe angina
attacks, fainting.
Drug Name

Generic Name : budesonide

Brand Name:
Inhalation: Entocort (CAN), Pulmicort Respules, Pulmicort Turbuhaler, Rhinocort Aqua, Rhinocort
Turbuhaler (CAN)
Oral: Entocort EC
Classification: Corticosteroid

Pregnancy Category B, C (oral)

Dosage & Route
PO Inflammatory bowel disease Active: 9 mg/day, up to 8 wk. Maintenance: 6 mg once daily,
up to 3 month. Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses, up
to 1.6 mg/day in severe cases. Maintenance: 200-400 mcg/day. As dry powd inhaler: 200-800
mcg/day. As nebulised soln: Inhale 1-2 mg twice daily. Maintenance: 0.5-1 mg twice daily. Nasal
Prophylaxis and treatment of rhinitis Initial: 200 mcg into each nostril daily, may reduce to 100
mcg into each nostril daily until symptoms are controlled. Nasal polyps 100 mcg twice daily into
each nostril for up to 3 month.

Therapeutic actions
Budesonide controls the rate of protein synthesis, depresses the migration of polymorphonuclear
leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular
level to prevent or control inflammation.

Indications
Management of symptoms of seasonal or perennial allergic rhinitis in adults and children;
nonallergic perennial rhinitis in adults
Turbuhaler: Maintenance treatment of asthma as prophylactic therapy in adults and children > 6
yr and for patients requiring corticosteroids for asthma
Inhalation suspension: Maintenance treatment and prophylaxis therapy of asthma in children 12
mo8 yr
Oral: Treatment and maintenance of clinical remission for up to 3 mo of mild to moderate active
Crohn's disease involving the ileum or ascending colon

Adverse effects
Loss of skin collagen and SC atrophy; local hypopigmentation of deeply pigmented skin; dryness,
irritation, epistaxis, rarely ulceration or perforation of the nasal septum; smell and taste
disturbances; hoarseness and candidiasis of the mouth or throat.

Contraindications
Hypersensitivity. Acute infections uncontrolled by antimicrobial chemotherapy.


Assessment
History: Untreated local nasal infections, nasal trauma, septal ulcers, recent nasal surgery,
lactation
Physical: BP, P, auscultation; R, adventitious sounds; examination of nares
Interventions

Inhalation
BLACK BOX WARNING: Taper systemic steroids carefully during transfer to inhalational
steroids; deaths from adrenal insufficiency have occurred.
Arrange for use of decongestant nose drops to facilitate penetration if edema, excessive
secretions are present.
Prime unit before use for Pulmicort Turbuhaler; have patient rinse mouth after each use.
Use aerosol within 6 mo of opening. Shake well before each use.
Store Respules upright and protected from light; gently shake before use; open envelopes should
be discarded after 2 wk.
Nasal inhalation
Prime pump eight times before first use. If not used for 2 consecutive days, reprime with 1 spray
or until fine mist appears. If not used for more than 14 days, rinse applicator and reprime with 2
sprays or until fine mist appears.
Oral
Make sure patient does not cut, crush, or chew capsules; they must be swallowed whole.
Administer the drug once each day, in the morning; do not administer with grapefruit juice.
Encourage patient to complete full 8 wk of drug therapy.
WARNING: Monitor patient for signs of hypercorticismacne, bruising, moon face, swollen
ankles, hirsutism, skin striae, buffalo humpwhich could indicate need to decrease dosage.
Teaching points

Inhalation
Do not use more often than prescribed; do not stop without consulting your health care provider.
It may take several days to achieve good effects; do not stop if effects are not immediate.
Use decongestant nose drops first if nasal passages are blocked.
Prime unit before use for Pulmicort Turbuhaler; rinse mouth after each use.
Store Respules upright, protect from light; discard open envelopes after 2 weeks; gently shake
before use.
You may experience these side effects: Local irritation (use your device correctly), dry mouth
(suck sugarless lozenges).
Report sore mouth, sore throat, worsening of symptoms, severe sneezing, exposure to
chickenpox or measles, eye infections.
Oral
Take the drug once a day in the morning. Do not cut, crush, or chew the capsules, they must be
swallowed whole.
If you miss a day, take the capsules as soon as you remember them. Take the next day's
capsules at the regular time. Do not take more than three capsules in a day.
Take the full course of the drug therapy (8 weeks in most cases).
Do not take this drug with grapefruit juice; avoid grapefruit juice entirely while using this drug.
Store Respules upright, protected from light; discard open envelopes after 2 weeks. Shake before
use.
You may experience these side effects: Dizziness, headache (avoid driving or operating
dangerous machinery if these effects occur); nausea, flatulence (small, frequent meals may help;
try to maintain your fluid and food intake).
Report chest pain, ankle swelling, respiratory infections, increased bruising.
Drug Name

Generic Name : epinephrine (adrenaline), epinephrine bitartrate, epinephrine borate, epinephrine
hydrochloride

Brand Name:
Aerosol: Primatene Mist
Ophthalmic solution: Epinal
Injection, OTC nasal solution: Adrenalin Chloride
Insect-sting emergencies: EpiPen Auto-Injector (delivers 0.3 mg IM adult dose), EpiPen Jr. Auto-
Injector (delivers 0.15 mg IM for children)
OTC solutions for nebulization: AsthmaNefrin, microNefrin, Nephron, S2
Classification: Sympathomimetic, Alpha-adrenergic agonist, Beta1- and beta2-adrenergic agonist,
Cardiac stimulant, Vasopressor, Bronchodilator, Antasthmatic, Nasal decongestant, Mydriatic


Dosage & Route

ADULTS

Epinephrine injection
Cardiac arrest: 0.51 mg (510 mL of 1:10,000 solution) IV or by intracardiac injection into left
ventricular chamber; during resuscitation, 0.5 mg q 5 min.
Intraspinal

0.20.4 mL of a 1:1,000 solution added to anesthetic spinal fluid mixture.
Other use with local anesthetic: Concentrations of 1:100,0001:20,000 are usually used.
1:1,000 solution
Respiratory distress: 0.30.5 mL of 1:1,000 solution (0.30.5 mg), subcutaneously or IM, q 20
min for 4 hr.
1:200 suspension (for subcutaneous administration only)
Respiratory distress: 0.10.3 mL (0.51.5 mg) subcutaneously.
Inhalation (aerosol)
Begin treatment at first symptoms of bronchospasm. Individualize dosage. Wait 15 min between
inhalations to avoid overdose.
Inhalation (nebulization)
Place 815 drops into the nebulizer reservoir. Place nebulizer nozzle into partially opened mouth.
Patient inhales deeply while bulb is squeezed one to three times. If no relief in 5 min, give 23
additional inhalations. Use four to six times per day usually maintains comfort.
Topical nasal solution
Apply locally as drops or spray or with a sterile swab, as required.
Ophthalmic solution
Vasoconstriction, mydriasis: Instill 12 drops into the eye or eyes; repeat once if necessary.
PEDIATRIC PATIENTS

Epinephrine injection
1:1,000 solution, children and infants except premature infants and full-term newborns: 0.01
mg/kg or 0.3 mL/m2 (0.01 mg/kg or 0.3 mg/m2) subcutaneously q 20 min (or more often if
needed) for 4 hr. Do not exceed 0.5 mL (0.5 mg) in a single dose.
1:200 suspension, infants and children (1 mo1 yr): 0.005 mL/kg (0.025 mg/kg) subcutaneously.
Children < 30 kg: Maximum single dose is 0.15 mL (0.75 mg). Administer subsequent doses only
when necessary and not more often than q 6 hr.
Topical nasal solution
> 6 yr: Apply locally as drops or spray or with a sterile swab, as required.
Ophthalmic solutions
Safety and efficacy for use in children not established.
GERIATRIC PATIENTS OR PATIENTS WITH RENAL FAILURE
Use with caution; patients > 60 yr are more likely to develop adverse effects.

Therapeutic actions
Epinephrine, an active principle of the adrenal medulla, is a direct-acting sympathomimetic. It
stimulates - and -adrenergic receptors resulting in relaxation of smooth muscle of the bronchial
tree, cardiac stimulation and dilation of skeletal muscle vasculature. It is frequently added to local
anaesthetics to retard diffusion and limit absorption, to prolong the duration of effect and to lessen
the danger of toxicity.

Indications
IV: In ventricular standstill after all other measures have failed to restore circulation, given by
trained personnel by intracardiac puncture and intramyocardial injection; treatment and
prophylaxis of cardiac arrest and attacks of transitory AV heart block with syncopal seizures
(Stokes-Adams syndrome); syncope due to carotid sinus syndrome; acute hypersensitivity
(anaphylactoid) reactions, serum sickness, urticaria, angioneurotic edema; in acute asthmatic
attacks to relieve bronchospasm not controlled by inhalation or subcutaneous injection; relaxation
of uterine musculature; additive to local anesthetic solutions for injection to prolong their duration
of action and limit systemic absorption
Injection: Relief from respiratory distress of bronchial asthma, chronic bronchitis, emphysema,
other COPDs
Aerosols and solutions for nebulization: Temporary relief from acute attacks of bronchial asthma,
COPD
Topical nasal solution: Temporary relief from nasal and nasopharyngeal mucosal congestion due
to a cold, sinusitis, hay fever, or other upper respiratory allergies; adjunctive therapy in middle ear
infections by decreasing congestion around eustachian ostia
0.1% ophthalmic solution: Conjunctivitis, during eye surgery to control bleeding, to produce
mydriasis

Adverse effects
CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary
retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of
extremities; hypokalaemia. Gangrene, tissue necrosis and sloughing (extravasation) when used
in addition to local anaesthetics. Eye drops: Severe smarting, blurred vision, photophobia; naso-
lachrymal ducts obstruction. Oedema, hyperaemia and inflammation of the eyes with repeated
administration.

Contraindications
Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops);
hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics:
Procedures involving digits, ears, nose, penis or scrotum.


Assessment
History: Allergy or hypersensitivity to epinephrine or components of drug preparation; narrow-
angle glaucoma; shock other than anaphylactic shock; hypovolemia; general anesthesia with
halogenated hydrocarbons or cyclopropane; organic brain damage, cerebral arteriosclerosis;
cardiac dilation and coronary insufficiency; tachyarrhythmias; ischemic heart disease;
hypertension; renal impairment; COPD; diabetes mellitus; hyperthyroidism; prostatic hypertrophy;
history of seizure disorders; psychoneuroses; labor and delivery; lactation; contact lens use,
aphakic patients (ophthalmic preparations)
Physical: Weight; skin color, T, turgor; orientation, reflexes, IOP; P, BP; R, adventitious sounds;
prostate palpation, normal urine output; urinalysis, renal function tests, blood and urine glucose,
serum electrolytes, thyroid function tests, ECG
Interventions
WARNING: Use extreme caution when calculating and preparing doses; epinephrine is a very
potent drug; small errors in dosage can cause serious adverse effects. Double-check pediatric
dosage.
Use minimal doses for minimal periods of time; "epinephrine-fastness" (a form of drug tolerance)
can occur with prolonged use.
Protect drug solutions from light, extreme heat, and freezing; do not use pink or brown solutions.
Drug solutions should be clear and colorless (does not apply to suspension for injection).
Shake the suspension for injection well before withdrawing the dose.
Rotate subcutaneous injection sites to prevent necrosis; monitor injection sites frequently.
WARNING: Keep a rapidly acting alpha-adrenergic blocker (phentolamine) or a vasodilator (a
nitrate) readily available in case of excessive hypertensive reaction.
WARNING: Have an alpha-adrenergic blocker or facilities for intermittent positive pressure
breathing readily available in case pulmonary edema occurs.
WARNING: Keep a beta-adrenergic blocker (propranolol; a cardioselective beta-adrenergic
blocker, such as atenolol, should be used in patients with respiratory distress) readily available in
case cardiac arrhythmias occur.
Do not exceed recommended dosage of inhalation products; administer pressurized inhalation
drug forms during second half of inspiration, because the airways are open wider and the aerosol
distribution is more extensive. If a second inhalation is needed, administer at peak effect of
previous dose, 35 min.
Use topical nasal solutions only for acute states; do not use for longer than 35 days, and do not
exceed recommended dosage. Rebound nasal congestion can occur after vasoconstriction
subsides.
Teaching points
Do not exceed recommended dosage; adverse effects or loss of effectiveness may result. Read
the instructions that come with respiratory inhalant products, and consult your health care
provider or pharmacist if you have any questions.
To give eye drops: Lie down or tilt head backward, and look up. Hold dropper above eye; drop
medicine inside lower lid while looking up. Do not touch dropper to eye, fingers, or any surface.
Release lower lid; keep eye open, and do not blink for at least 30 seconds. Apply gentle pressure
with fingers to inside corner of the eye for about 1 minute; wait at least 5 minutes before using
other eye drops.
You may experience these side effects: Dizziness, drowsiness, fatigue, apprehension (use
caution if driving or performing tasks that require alertness); anxiety, emotional changes; nausea,
vomiting, change in taste (eat frequent small meals); fast heart rate. Nasal solution may cause
burning or stinging when first used (transient). Ophthalmic solution may cause slight stinging
when first used (transient); headache or brow ache (only during the first few days).
Report chest pain, dizziness, insomnia, weakness, tremor or irregular heart beat (respiratory
inhalant, nasal solution), difficulty breathing, productive cough, failure to respond to usual dosage
(respiratory inhalant), decrease in visual acuity (ophthalmic).
Drug Name

Generic Name : lidocaine hydrochloride ,lidocaine HCl in 5% dextrose , lidocaine HCl without
preservatives

Brand Name:
Antiarrhythmic preparations: Xylocaine HCl IV for Cardiac Arrhythmias
Local anesthetic preparations: Octocaine, Xylocaine HCl (injectable)
Topical for mucous membranes: Anestacon, Burn-O-Jel, Dentipatch, DermaFlex, ELA-Max,
Xylocaine, Zilactin-L
Topical dermatologic: Lidoderm, Numby Stuff, Xylocaine
Classification: Antiarrhythmic, Local anesthetic

Pregnancy Category B

Dosage & Route

ADULTS

IM
Arrhythmia: Use only the 10% solution for IM injection. 300 mg in deltoid or thigh muscle. Switch
to IV lidocaine or oral antiarrhythmic as soon as possible.
IV bolus
Arrhythmia: Use only lidocaine injection labeled for IV use and without preservatives or
catecholamines. Monitor ECG constantly. Give 50100 mg at rate of 2550 mg/min. One-third to
one-half the initial dose may be given after 5 min if needed. Do not exceed 200300 mg in 1 hr.
IV, continuous infusion
Arrhythmia: Give 14 mg/min (or 2050 mcg/kg/min). Titrate the dose down as soon as the
cardiac rhythm stabilizes. Use lower doses in patients with CHF, liver disease, and in patients >
70 yr.
Topical, intratissue, epidural
Local anesthesia: Preparations containing preservatives should not be used for spinal or epidural
anesthesia. Drug concentration and diluent should be appropriate to particular local anesthetic
use: 5% solution with glucose is used for spinal anesthesia, 1.5% solution with dextrose for low
spinal or "saddle block"; anesthesia. Dosage varies with the area to be anesthetized and the
reason for the anesthesia; use the lowest dose possible to achieve results.
PEDIATRIC PATIENTS

IV
Arrhythmia: Safety and efficacy have not been established. American Heart Association
recommends bolus of 0.51 mg/kg IV, followed by 30 mcg/kg/min with caution. The IM auto-
injector device is not recommended.
Topical, intratissue, epidural
Local anesthesia: See adult dosage discussion. Use lower concentrations.
GERIATRIC OR DEBILITATED PATIENTS, PATIENTS WITH LIVER DISEASE OR CHF
Use lower concentrations in these patients.

Therapeutic actions
Lidocaine is an amide type local anesthetic. It stabilizes the neuronal membrane and inhibits
sodium ion movements, which are necessary for conduction of impulses. In the heart, lidocaine
reduces phase 4 depolarization and automaticity. Duration of action potential and effective
refractory period are also reduced.

Indications
As antiarrhythmic: Management of acute ventricular arrhythmias during cardiac surgery and MI
(IV use). Use IM when IV administration is not possible or when ECG monitoring is not available
and the danger of ventricular arrhythmias is great (single-dose IM use, for example, by
paramedics in a mobile coronary care unit)
As anesthetic: Infiltration anesthesia, peripheral and sympathetic nerve blocks, central nerve
blocks, spinal and caudal anesthesia, retrobulbar and transtracheal injection; topical anesthetic
for skin disorders and accessible mucous membranes

Adverse effects
Dizziness, paresthesia, drowsiness, confusion, respiratory depression and convulsions.
Potentially Fatal: Hypotension and bradycardia leading to cardiac arrest; anaphylaxis

Contraindications
Hypovolemia; heart block or other conduction disturbances.


Assessment
History: Allergy to lidocaine or amide-type local anesthetics, CHF, cardiogenic shock, second- or
third-degree heart block, Wolff-Parkinson-White syndrome, Stokes-Adams syndrome, hepatic or
renal disease, inflammation or sepsis in region of injection, lactation, pregnancy
Physical: T; skin color, rashes, lesions; orientation, speech, reflexes, sensation and movement
(local anesthetic); P, BP, auscultation, continuous ECG monitoring during use as antiarrhythmic;
edema; R, adventitious sounds; bowel sounds, liver evaluation; urine output; serum electrolytes,
LFTs, renal function tests
Interventions
WARNING: Check drug concentration carefully; many concentrations are available.
Reduce dosage with hepatic or renal failure.
Continuously monitor response when used as antiarrhythmic or injected as local anesthetic.
WARNING: Keep life-support equipment and vasopressors readily available in case severe
adverse reaction (CNS, CV, or respiratory) occurs when lidocaine is injected.
WARNING: Establish safety precautions if CNS changes occur; have IV diazepam or short-acting
barbiturate (thiopental, thiamylal) readily available in case of seizures.
WARNING: Monitor for malignant hyperthermia (jaw muscle spasm, rigidity); have life-support
equipment and IV dantrolene readily available.
WARNING: Establish safety precautions if CNS changes occur; have IV diazepam or short-acting
barbiturate (thiopental, thiamylal) readily available in case of seizures.
WARNING: Monitor for malignant hyperthermia (jaw muscle spasm, rigidity); have life-support
equipment and IV dantrolene readily available.
Titrate dose to minimum needed for cardiac stability, when using lidocaine as antiarrhythmic.
Reduce dosage when treating arrhythmias in CHF, digitalis toxicity with AV block, and geriatric
patients.
Monitor fluid load carefully; more concentrated solutions can be used to treat arrhythmias in
patients on fluid restrictions.
Have patients who have received lidocaine as a spinal anesthetic remain lying flat for 612 hr
afterward, and ensure that they are adequately hydrated to minimize risk of headache.
WARNING: Check lidocaine preparation carefully; epinephrine is added to solutions of lidocaine
to retard the absorption of the local anesthetic from the injection site. Be sure that such solutions
are used only to produce local anesthesia. These solutions should be injected cautiously in body
areas supplied by end arteries and used cautiously in patients with peripheral vascular disease,
hypertension, thyrotoxicosis, or diabetes.
Use caution to prevent choking. Patient may have difficulty swallowing following use of oral
topical anesthetic. Do not give food or drink for 1 hr after use of oral anesthetic.
Apply lidocaine ointments or creams to a gauze or bandage before applying to the skin.
WARNING: Monitor for safe and effective serum drug concentrations (antiarrhythmic use: 15
mcg/mL). Doses > 610 mcg/mL are usually toxic.
Teaching points
Dosage is changed frequently in response to cardiac rhythm on monitor.
Oral lidocaine can cause numbness of the tongue, cheeks, and throat. Do not eat or drink for 1
hour after using oral lidocaine to prevent biting the inside of your mouth or tongue and choking.
You may experience these side effects: Drowsiness, dizziness, numbness, double vision;
nausea, vomiting; stinging, burning, local irritation (local anesthetic).
Report difficulty speaking, thick tongue, numbness, tingling, difficulty breathing, pain or numbness
at IV site, swelling, or pain at site of local anesthetic use.

Generic Name: Paracetamol, Acetaminophen
Brand Name: Biogesic, Panadol, Tylenol
Classification: Non-narcotic analgesic, Antipyretic
Uses:
1. Control of pain due to headache, earache, dysmenorrhea, arthralgia, myalgia,
musculoskeletal pain, arthritis, immunizations, teething, tonsillectomy
2. O reduce fever in viral and bacterial infections
3. As a substitute for aspirin in upper GI disease, bleeding disorders clients in anticoagulant
therapy and gouty arthritis
Actions:
1. Decreases fever by a hypothalamic effect leading to sweating and vasodilation
2. Inhibits pyrogen effect on the hypothalamic-heat-regulating centers
3. Inhibits CNS prostaglandin synthesis with minimal effects on peripheral prostaglandin
synthesis
4. Does not cause ulceration of the GI tract and causes no anticoagulant action.
Contraindications:
1. Renal Insufficiency
2. Anemia
Special Concerns:
1. Liver toxicity (hepatocyte necrosis) may occur with doses not far beyond labeled dosing.
2. If 3 or more alcoholic drinks per day is consumed, consult a physician prior use.
Side-Effects:
1. Minimal GI upset.
2. Methemoglobinemia
3. Hemolytic Anemia
4. Neutropenia
5. Thrombocytopenia
6. Pancytopenia
7. Leukopenia
8. Urticaria
9. CNS stimulation
10. Hypoglycemic coma
11. Jaundice
12. Glissitis
13. Drowsiness
14. Liver Damage
Dosage:
Per Orem: 325-650mg q4h up to a maximum of 1 gram q6h.
Suppositories: 650mg q4h not to exceed 4 grams a day for up to 10 days.
Nursing Considerations:
1. Do not exceed 4gm/24hr. in adults and 75mg/kg/day in children.
2. Do not take for >5days for pain in children, 10 days for pain in adults, or more than 3
days for fever in adults.
3. Extended-Release tablets are not to be chewed.
4. Monitor CBC, liver and renal functions.
5. Assess for fecal occult blood and nephritis.
6. Avoid using OTC drugs with Acetaminophen.
7. Take with food or milk to minimize GI upset.
8. Report N&V. cyanosis, shortness of breath and abdominal pain as these are signs of
toxicity.
9. Report paleness, weakness and heart beat skips
10. Report abdominal pain, jaundice, dark urine, itchiness or clay-colored stools.
11. Phenmacetin may cause urine to become dark brown or wine-colored.
12. Report pain that persists for more than 3-5 days
13. Avoid alcohol.
14. This drug is not for regular use with any form of liver disease.
Ketorolac tromethamine also known as Ketorolac is a type of non-steroidal anti-inflammatory
drug which is widely used as analgesic. On November 30, 1989, this drug was been approved by
the FDA and introduced in the market by Syntex as Toradol. Aside from its analgesic effect, it is
also used as anti-inflammatory that inhibits leukotriene and prostaglandin synthesis. This drug
should only be used in a short term basis especially in the treatment of pain (up to five days). It is
also used for ophthalmic relief of ocular itching brought by seasonal conjunctivitis and in cases
of postoperative inflammation after cataract surgery.
Available forms:
Ketorolac Tromethamine is available in three forms:
Injection 15, 30 mg/mL, Ophthalmic solution 0.4% (LS), 0.5% and Tablets 10 mg
Dosages:
Ketorolac is considered a potent non-steroidal anti-inflammatory drug with various adverse
effects.
A. Adults
1. Oral
Transfer to oral: 20 mg PO as first dose for patients who received 60 mg IM or 30 mg IV as a
single dose or 30 mg multiple dose, followed by 10 mg every four to six hours; do not exceed 40
mg/24 hr.
2. Ophthalmic
Acular LS: 1 drop qid prn for stinging and burning; use this drug up to 3 days after
surgery.
Itching due to allergic conjunctivitis: 1 drop qid
Acular, Acular PF: For cataract surgery, begin by 1 drop qid 24 hours after and continue
for two weeks.
3. Parenteral
Single dose treatment: 60 mg IM or 30 mg IV
Multiple dose treatment: 30 mg IM or IV every six hours to a maximum 120 mg/day.
B. Geriatric patients 65 years old and above, patients who weigh less than 50 kg, and patients
with renal impairment
1. Oral
Transfer to oral: 10 mg PO as first dose for patients who received 30 mg IM or 15 mg IV single
dose or 15 mg IV or IM in multiple dose, then 10 mg PO every four to six hours; do not exceed
using this drug 40 mg/24 hr.
2. Parenteral
Single dose treatment: 30 mg IM or 15 mg IV
Multiple dose treatment: 15 mg IM or IV every six hours to a maximum of 60 mg/day
C. Pediatric patients: Ketorolacs safety and efficiency are not yet proven.
Drug Interactions:
It has an increased risk of nephrotoxicity when use with other nephrotoxins (e.g. cyclosporine);
increased risk of bleeding when use with anticoagulants (e.g. warfarin).
Pharmacokinetics:
When ketorolac is given orally, the onset varies; the peak is usually 30 to 60 minutes for six
hours duration of drug. If this drug is given through IM or IV, the onset is 30 minutes; the peak is
1-2 hours for six hours duration.
The distribution of this drug crosses the placenta and enters the breast milk. The excretion is
same with other drugs i.e. through urine.
Contraindications and Cautions:
1. This drug should be use cautiously with patients who have impaired hearing, allergies,
and cardiovascular/gastrointestinal/hepatic conditions.
2. It is contraindicated during labor and delivery and mothers who gives breastfeeding to
their baby.
3. Contraindicated to patients who wears soft contact lenses.
4. Contraindicated to patients who use NSAIDS simultaneously.
5. Contraindicated to patients who have a history of gastrointestinal bleeding or peptic
ulcer.
6. Contraindicated to patients who are suspected or confirmed cerebrovascular bleeding.
Adverse Effects:
1. Respiratory: rhinitis, hemoptysis, dyspnea
2. GI: GI pain, diarrhea, vomiting, nausea
3. CNS: dizziness, fatigue, insomnia, headache
4. Hematologic: neutropenia, leukopenia, decreased Hgb or Hct, bone marrow depression
5. Dermatologic: sweating, dry mucous membrane, pruritus
Nursing Interventions/Considerations:
1. Dont forget to assess first the patient before administering this drug: know the history
(e.g. allergies, renal impairment, etc.) and physical condition of the patient (reflexes,
ophthalmologic and audiometric evaluation, orientation, clotting times, serum
electrolytes, etc.)
2. In case of hypersensitivity, be sure that emergency equipment is available.
3. Drug vials should be protected from light.
4. To maintain serum levels and control pain effectively, administer it every six hours.
5. Report any signs of itching, swelling in the ankles, sore throat, easy bruising, etc.
Generic Name: Captopril
Brand Names: Capoten, Acepril, Ace-Bloc, Bloc-Med, Capomed, Capotec, Captogen, Captor,
Captril, Cardiovaz
Classification: ACE Inhibitor
Pregnancy Category: D
Route: Oral
Preparations: 12.5, 25, 50, 100 mg
Indication: Captopril is used alone or in combination of other drugs for the management of
hypertension. It is also used in combination with other drugs in the treatment of heart failure
after a heart attack. Also used to treat kidney problems caused by diabetic nephropathy.
Contraindications: Allergy to other ACE inhibitors. Aortic stenosis, outflow obstruction,
renovascular disease. Pregnancy and Lactation. Caution in cases where patients also have
Leukemia, COPD, renal or thyroid disease.
Action: Used to block the action of angiotensin converting enzyme (ACE) which is naturally
produced in the body. ACE produces angiotensin II which causes constriction and narrowing of
the blood vessels thereby increasing blood pressure. By blocking ACE, production of angiotensin
II decreases allowing the blood vessels to relax and widen resulting in decrease blood pressure.
Therapeutic Effect: Lowers blood pressure and increases blood and oxygen supply to the heart
in patients with hypertension. Decreases preload and afterload for patients with heart failure.
Slows down or reduces progression of blood vessels disease within the kidney caused by high
blood pressure in patients with diabetic nephropathy.
Dosage: Hypertension: Initial dose of 12.5 mg twice a day, increase gradually at 2-4wk interval.
Maintenance dose of 25-50 mg twice a day, maximum of 50 mg thrice a day. Heart Failure:
Initial dose of 6.25mg-12.5mg. Maintenance dose of 25 or 50 mg bid, maximum dose of 50 mg
tid.
Diabetic Nephropathy: 75-100mg daily in divided doses.
Pharmacokinetics:
Absorption: Rapidly absorbed (75%) from the GI tract. Food decreases absorption.
Distribution: Widely distributed but does not cross the blood brain barrier. Crosses the placenta,
small amounts enter breast milk.
Metabolism and Excretion: 50% metabolized by the liver. 50% excreted unchanged by the
kidneys.
Pharmacodynamics:
Onset: 15- 60 min
Peak: 60-90 min
Duration: 6-12 hr
Side Effects: hypotension, dizziness, dry mouth, itching, sleep problems, rashes, diarrhea,
constipation, hair loss, dry irritating cough, changes in the way things taste, upset stomach,
abdominal pain, shortness of breath, agranulocytosis, neutropenia
Interactions: Additive hypotension with other antihypertensive, phenothiazines, acute ingestion
of alcohol and vasodilators. Hyperkalemia may result from concurrent use of potassium
supplements or potassium-sparing diuretics, Antihypertensive response may be blunted by non-
steroidal anti-inflammatory agents. Absorption may be decreased by antacids. Increases levels
and may increase risk of digoxin or lithium toxicity. Probenecid decreases elimination and
increases levels of captopril. Risk of hypersensitivity reactions increased by concurrent use of
allopurinol.
Nursing Considerations
Monitor blood pressure and pulse frequently.
Monitor weight and assesses patient frequently for signs of fluid overload if with
concurrent diuretic therapy.
assessments of urine protein may be ordered. Proteinuria and nephrotic syndrome may
occur with therapy.
Monitor BUN, Crea and electrolyte levels periodically.
WBC should be monitored prior to therapy and periodically thereafter.
May cause false positive result for urine acetone
Patient/Family Health Teachings
Instruct patient to take captopril exactly as directed. Missed dose should be taken as soon
as remembered but not if almost time for next dose.
Do not double doses.
Instruct patient not to discontinue captopril therapy unless directed by health care
provider.
Encourage patient to comply with additional interventions for hypertension.
Instruct patient and family on proper technique of blood pressure monitoring. Advice
them to check blood pressure at least weekly and to report any significant changes.
Caution patient to avoid foods containing high levels of sodium or potassium.
Advice patient that any changes in taste sensation will reverse itself within 8-12 weeks.
Instruct patient to change position slowly to minimize occurrence of orthostatic
hypotension.
Advice patient that exercising in hot weather may increase hypotensive effect.
Instruct patient to consult with a health care provider before taking any over the counter
medications or cold remedies.
Advice patient of ingesting excessive amount of tea, coffee or cola.
Advice patient to avoid driving or other activities that require alertness until response to
therapy is known.
Instruct patient to notify health care provider if rash, sore throat, fever, irregular heart
beat, chest pain, swelling of face, eyes, lips or tongue and difficulty of breathing occurs.
Emphasize importance of follow up examinations for monitoring purposes.
Brand Name: Buscopan
Generic Name: Hyoscine-N-butylbromide
Classification: Antispasmodics
Pregnancy Category: C
Availability: Tablet 10 mg,Ampule 20mg
Action: The mechanism of action of Buscopan is that it blocks the muscarinic receptors found
on the smooth muscle walls which means its blocks the action of acetylcholine on the receptors
found within the smooth muscle of the gastrointestinal and urinary tract and thus reduces the
spasms and contractions. This relaxes the muscle and thus reduced the pain from the cramps and
spasms.
Indication:
1. Spasm in the genitourinary tract
2. Spasm in the gastrointestinal tract
3. Spasm in the biliary tract
4. Colic
Contraindications: Myasthenia gravies, megacolon, hypersensitivity to drug contents, narrow
angle glaucoma, prostate hypertrophy with urinary retention, mechanical stenosis in the GI tract,
tachycardia.
Cautious Use: Thyrotoxicosis, cardiac insufficiency, pyrexia, fructose intolerance.
Route & Dosage
Tablet Adult and child >6 y/o 1 to 2 tab TID-QID
Ampule
Colic Pain Adult and adolescent >12 y/o 1-2 amp IV/IM/SC several times daily. Maximum dose:
100mg/day
Infant and young children 0.3-0.6 mg/kg/body weight by slow IV/IM/SC several times daily.
Maximum dose: 1.5 mg/kg/body weight.
Adverse effects:
1. Constipation
2. Decreased sweating
3. Mouth, skin, eye dryness
4. Blurred feeling
5. Bloating
6. Dysuria
7. Nausea or vomiting
8. Lightheadedness
9. Headache
10. Weakness
Drug Interaction:
1. Potassium chloride
2. Metoclopramide
3. MAO inhibitors
4. Beta-agonists
5. Anticholinergics
6. Antacids
7. Droperidol
Patient & Family Education
1. Take this drug 30 minutes to 1 hour before meals
2. Buscopan will potentiate the effect of alcohol and other CNS depressants.
3. Do not take antacids and antidiarrheal 2 to 3 hours prior to raking this drug.
4. It is not necessary to take the medication if you are not in pain.
5. Avoid driving or operating machinery after parenteral dose.
Generic Name:Metoclopramide
Brand Name:Clopra, Emex , Maxeran , Maxolon, Reglan
Classifications:gastrointestinal agent; prokinetic agent (gi stimulant); autonomic nervous system
agent; direct-acting cholinergic (parasympathomimetic); antiemetic
Pregnancy Category:B
Availability
5 mg, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL injection
Actions
Potent central dopamine receptor antagonist. Structurally related to procainamide but has little
antiarrhythmic or anesthetic activity. Exact mechanism of action not clear but appears to
sensitize GI smooth muscle to effects of acetylcholine by direct action.
Therapeutic effects
Increases resting tone of esophageal sphincter, and tone and amplitude of upper GI contractions.
As a result, gastric emptying and intestinal transit are accelerated with little effect, if any, on
gastric, biliary, or pancreatic secretions. Antiemetic action results from drug-induced elevation
of CTZ threshold and enhanced gastric emptying. In diabetic gastroparesis, indicated by relief of
anorexia, nausea, vomiting, persistent fullness after meals.
Uses
Management of diabetic gastric stasis (gastroparesis); to prevent nausea and vomiting associated
with emetogenic cancer chemotherapy (e.g., cisplatin, dacarbazine); to facilitate intubation of
small bowel; symptomatic treatment of gastroesophageal reflux.
Contraindicatons
Sensitivity or intolerance to metoclopramide; allergy to sulfiting agents; history of seizure
disorders; concurrent use of drugs that can cause extrapyramidal symptoms; pheochromocytoma;
mechanical GI obstruction or perforation; history of breast cancer. Safety during pregnancy
(category B) or lactation is not established.
Cautious Use
CHF; hypokalemia; kidney dysfunction; GI hemorrhage; history of intermittent porphyria.
Route & Dosage
Gastroesophageal Reflux
adult:PO 1015 mg q.i.d. a.c. and h.s.
child:PO/IV/IM 0.40.8 mg/kg/d in 4 divided doses
Diabetic Gastroparesis
adult:PO 10 mg q.i.d. a.c. and h.s. for 28 wk
geriatric:PO 5 mg a.c and h.s.
Small-bowel Intubation, Radiologic Examination
adult:IM/IV 10 mg administered over 12 min
child:IM/IV <6 y, 0.1 mg/kg over 12 min; 614 y, 2.55 mg over 12 min
Chemotherapy-induced Emesis
adultchild:PO 2 mg/kg 1 h before antineoplastic administration, may repeat q2h for 3 more
doses if needed
IM/IV 2 mg/kg 30 min before antineoplastic administration, may repeat q2h for 2 doses, then
q3h for 3 doses if needed
Adverse effects:
CNS:restlessness,drowsiness,fatigue,insomia,dizziness,anxiety
CV:tansient hypertension
GI:nausea and diarrhea
Nursing Implications
Assessment & Drug Effects
Report immediately the onset of restlessness, involuntary movements, facial grimacing,
rigidity, or tremors. Extrapyramidal symptoms are most likely to occur in children, young
adults, and the older adult and with high-dose treatment of vomiting associated with
cancer chemotherapy. Symptoms can take months to regress.
Be aware that during early treatment period, serum aldosterone may be elevated; after
prolonged administration periods, it returns to pretreatment level.
Lab tests: Periodic serum electrolyte.
Monitor for possible hypernatremia and hypokalemia, especially if patient has CHF or
cirrhosis.
Adverse reactions associated with increased serum prolactin concentration (galactorrhea,
menstrual disorders, gynecomastia) usually disappear within a few weeks or months after
drug treatment is stopped.
Avoid driving and other potentially hazardous activities for a few hours after drug
administration.
Avoid alcohol and other CNS depressants.
Report S&S of acute dystonia, such as trembling hands and facial
grimacing,immediately.
Do not breast feed while taking this drug without consulting physician.
Generic Name: Calcium Gluconate
Brand Name: Kalcinate
Classifications: fluid and electrolytic and water balance agent; replacement solution
Pregnancy Category: B
Availability
500 mg, 650 mg, 975 mg, 1 gm tablets; 10% injection
Actions
Calcium is an essential element for regulating the excitation threshold of nerves and muscles, for
blood clotting mechanisms, cardiac function (rhythm, tonicity, contractility), maintenance of
renal function, for body skeleton and teeth. Also plays a role in regulating storage and release of
neurotransmitters and hormones; regulating amino acid uptake and absorption of vitamin B12,
gastrin secretion, and in maintaining structural and functional integrity of cell membranes and
capillaries. Calcium gluconate acts like digitalis on the heart, increasing cardiac muscle tone and
force of systolic contractions (positive inotropic effect).
Therapeutic effects
Rapidly and effectively restores serum calcium levels in acute hypocalcemia of various origins
and effective cardiac stabilizer under conditions of hyperkalemia or resuscitation.
Uses
Negative calcium balance (as in neonatal tetany, hypoparathyroidism, vitamin D deficiency,
alkalosis). Also to overcome cardiac toxicity of hyperkalemia, for cardiopulmonary resuscitation,
to prevent hypocalcemia during transfusion of citrated blood. Also as antidote for magnesium
sulfate, for acute symptoms of lead colic, to decrease capillary permeability in sensitivity
reactions, and to relieve muscle cramps from insect bites or stings. Oral calcium may be used to
maintain normal calcium balance during pregnancy, lactation, and childhood growth and to
prevent primary osteoporosis. Also in osteoporosis, osteomalacia, chronic hypoparathyroidism,
rickets, and as adjunct in treatment of myasthenia gravis and Eaton-Lambert syndrome.
Contraindicatons
Ventricular fibrillation, metastatic bone disease, injection into myocardium; administration by
SC or IM routes; renal calculi, hypercalcemia, predisposition to hypercalcemia
(hyperparathyroidism, certain malignancies); pregnancy (category B).
Cautious use
Digitalized patients, renal or cardiac insufficiency, sarcoidosis, history of lithiasis, immobilized
patients; lactation.
Route & Dosage
Supplement for Osteoporosis
adult: PO 12 g b.i.d. to q.i.d.
IV 7 mEq q 13d
child: PO 4565 mg/kg/d in divided doses.
IV 17 mEq q 13d
neonate: PO 50130 mg/kg/d (max 1 g).
IV mEq q 13d
Hypocalcemic Tetany
adult: IV 4.516 mEq prn
child: IV 0.50.7 mEq/kg t.i.d. or q.i.d.
neonate: IV 2.4 mEq/kg/d in divided doses
CPR
adult: IV 2.33.7 mEq x 1
Hyperkalemia with Cardiac Toxicity
adult: IV 2.2514 mEq q 12 min
Exchange Transfusions with Citrated Blood
adult: IV 1.35 mEq for each 100 mL of blood
neonate: IV 0.45 mEq for each 100 mL of blood
Administration
Oral
Ensure that chewable tablets are chewed or crushed before being swallowed with a liquid.
Give with meals to enhance absorption.
Intravenous

PREPARE direct: May be given undiluted intermittent: /continuous: May be diluted in 1000
mL of NS.
ADMINISTER direct: Give direct IV at a rate of 0.5 mL or a fraction thereof over 1 min. Do
not exceed 2 mL/min. intermittent: /continuous: Give slowly, not to exceed 200 mg/min,
through a small-bore needle into a large vein to avoid possibility of extravasation and resultant
necrosis. With children, scalp veins should be avoided. Avoid rapid infusion. High
concentrations of calcium suddenly reaching the heart can cause fatal cardiac arrest.
Incompatibilities Solution / Additive: Amphotericin B, cefamandole, dobutamine,
methylprednisolone, metoclopramide. Y-site: Amphotericin B cholesteryl complex, fluconazole,
Indomethacin.
Injection should be stopped if patient complains of any discomfort. Patient should be
advised to remain in bed for 1530 min or more following injection, depending on
response.
Adverse Effects
BodyWhole: Tingling sensation. With rapid IV, sensations of heat waves (peripheral
vasodilation), fainting.
GI: PO preparation: Constipation, increased gastric acid secretion.
CV: (With rapid infusion) hypotension, bradycardia, cardiac arrhythmias, cardiac arrest,
Skin: Pain and burning at IV site, severe venous thrombosis, necrosis and sloughing (with
extravasation).
Nursing Implications
Assess for cutaneous burning sensations and peripheral vasodilation, with moderate fall
in BP, during direct IV injection.
Monitor ECG during IV administration to detect evidence of hypercalcemia: decreased
QT interval associated with inverted T wave.
Observe IV site closely. Extravasation may result in tissue irritation and necrosis.
Monitor for hypocalcemia and hypercalcemia.
Lab tests: Determine levels of calcium and phosphorus (tend to vary inversely) and
magnesium frequently, during sustained therapy. Deficiencies in other ions, particularly
magnesium, frequently coexist with calcium ion depletion.
Report S&S of hypercalcemia promptly to your care provider.
Milk and milk products are the best sources of calcium (and phosphorus). Other good
sources include dark green vegetables, soy beans, tofu, and canned fish with bones.
Calcium absorption can be inhibited by zinc-rich foods: nuts, seeds, sprouts, legumes, soy
products (tofu).
Check with physician before self-medicating with a calcium supplement.
Generic Name:Sodium Bicarbonate
Brand Name:Sodium Bicarbonate
Classifications:gastrointestinal agent; antacid; fluid and electrolyte balance agent
Pregnancy Category:C
Availability
325 mg, 520 mg, 650 mg tablets; 4.2%, 5%, 7.5%, 8.4% injection
Actions
Short-acting, potent systemic antacid. Rapidly neutralizes gastric acid to form sodium chloride,
carbon dioxide, and water. After absorption of sodium bicarbonate, plasma alkali reserve is
increased and excess sodium and bicarbonate ions are excreted in urine, thus rendering urine less
acid. Not suitable for treatment of peptic ulcer because it is short-acting, high in sodium, and
may cause, gastric, distention, systemic, alkalosis, and possibly acid-rebound.
Therapeutic effects
Shortacting, potent systemic antacid; rapidly neutralizes gastric acid or systemic acidosis.
Uses
Systemic alkalinizer to correct metabolic acidosis (as occurs in diabetes mellitus, shock, cardiac
arrest, or vascular collapse), to minimize uric acid crystallization associated with uricosuric
agents, to increase the solubility of sulfonamides, and to enhance renal excretion of barbiturate
and salicylate overdosage. Commonly used as home remedy for relief of occasional heartburn,
indigestion, or sour stomach. Used topically as paste, bath, or soak to relieve itching and minor
skin irritations such as sunburn, insect bites, prickly heat, poison ivy, sumac, or oak. Sterile
solutions are used to buffer acidic parenteral solutions to prevent acidosis. Also as a buffering
agent in many commercial products (e.g., mouthwashes, douches, enemas, ophthalmic
solutions).
Contraindications
Prolonged therapy with sodium bicarbonate; patients losing chloride (as from vomiting, GI
suction, diuresis); heart disease, hypertension; renal insufficiency; peptic ulcer; pregnancy
(category C).
Cautious use
Edema, sodium-retaining disorders; lactation; older adults patients.
Route & dosage
Antacid
Adult:PO 0.32 g 14 times/d or 1/2 tsp of powder in glass of water
Urinary Alkalinizer
Adult:PO 4 g initially, then 12 g q4h
Child:PO 84840 mg/kg/d in divided doses
Cardiac Arrest
Adult:IV 1 mEq/kg of a 7.5% or 8.4% solution initially, then 0.5 mEq/kg q10min depending on
arterial blood gas determinations (8.4% solutions contain 50 mEq/50 mL), give over 12 min
Child:IV 0.51 mEq/kg of a 4.2% solution q10min depending on arterial blood gas
determinations, give over 12 min
Metabolic Acidosis
Adult:IV 25 mEq/kg by IV infusion over 48 h
Infant:IV 23 mEq/kg/d of a 4.2% solution over 48 h
Administration
Oral
Do not add oral preparation to calcium-containing solutions.
Topical
Use manufacturers directions: Bath or soak, 1/2 cup or more into tub of warm water;
Footsoak, 4 tbsp/L(qt) warm water; soak 510 min; Paste, 3 parts sodium bicarbonate to
1 part water
Note: Solutions in water slowly decompose, decomposition is accelerated by agitating or
warming the solution.
Intravenous

PREPARE IV Infusion: May give 4.2% (0.5 mEq/ml) and 5% (0.595 mEq/ml) NaHCO3
solutions undiluted. Dilute 7.5% (0.892 mEq/ml) and 8.4% (1 mEq/ml) solutions with
compatible IV solutions. Dilute to at least 4.2% for infants and children.
ADMINISTER IV Infusion: Give a bolus dose only in emergency situations. Usually, the rate
is 25 mEq/kg over 48 h; do not exceed 50 mEq/h. Stop infusion immediately if extravasation
occurs. Severe tissue damage has followed tissue infiltration.

Adverse effects
GI:Belching, gastric distention, flatulence.
Metabolic:Metabolic alkalosis; electrolyte imbalance: sodium overload (pulmonary edema),
hypocalcemia (tetany), hypokalemia, milk-alkali syndrome, dehydration.
other:Rapid IV in neonates (Hypernatremia, reduction in CSF pressure, intracranial
hemorrhage).
Skin:Severe tissue damage following extravasation of IV solution.
Urogenital:Renal calculi or crystals, impaired kidney function.
Nursing implications
Be aware that long-term use of oral preparation with milk or calcium can cause milk-
alkali syndrome: Anorexia, nausea, vomiting, headache, mental confusion,
hypercalcemia, hypophosphatemia, soft tissue calcification, renal and ureteral calculi,
renal insufficiency, metabolic alkalosis.
Lab tests: Urinary alkalinization: Monitor urinary pH as a guide to dosage (pH testing
with nitrazine paper may be done at intervals throughout the day and dosage adjustments
made accordingly).
Lab tests: Metabolic acidosis: Monitor patient closely by observations of clinical
condition; measurements of acid-base status (blood pH, Po2, Pco2, Hco3-, and other
electrolytes, are usually made several times daily during acute period).
Observe for signs of alkalosis (over treatment)
Observe for and report S&S of improvement or reversal of metabolic acidosis.
Do not use sodium bicarbonate as antacid. A nonabsorbable OTC alternative for repeated
use is safer.
Do not take antacids longer than 2 wk except under advice and supervision of a
physician. Self-medication with routine doses of sodium bicarbonate or soda mints may
cause sodium retention and alkalosis, especially when kidney function is impaired.
Be aware that commonly used OTC antacid products contain sodium bicarbonate: Alka-
Seltzer, Bromo-Seltzer, Gaviscon.
Potassium Chloride
Apo-K , K-10, Kalium Durules,Kaochlor,Kaochlor-20 Concentrate, Kaon-Cl, Kato, Kay Ciel,
KCl 5% and 20%, K-Long , Klor, Klor-10%, Klor-Con, Kloride, Klorvess, Klotrix, K-Dur, K-
Lyte/Cl, K-tab, Micro-K Extentabs, Novolente K , Roychlor 10% and 20% , Rum-K, SK-
PotassiumChloride, Slo-Pot , Slow-K
Potassium Gloconate
Kaon, Kaylixir, K-G Elixir, Potassium Rougier , Royonate
Classifications: electrolytic and water balance agent; replacement solution
Pregnancy Category: A
Availability
6.7 mEq, 8 mEq, 10 mEq, 20 mEq sustained release tablets; 500 mg, 595 mg tablets; 20 mEq,
25 mEq, 50 mEq effervescent tablets; 20 mEq/15 mL, 40 mEq/15 mL, 45 mEq/15 mL liquid;
15 mEq, 20 mEq, 25 mEq powder; 2 mEq/mL injection; 10 mEq, 20 mEq, 30 mEq, 40 mEq, 60
mEq, 90 mEq vials; 20 mEq/15 mL liquid
Actions
Principal intracellular cation; essential for maintenance of intracellular isotonicity, transmission
of nerve impulses, contraction of cardiac, skeletal, and smooth muscles, maintenance of normal
kidney function, and for enzyme activity. Plays a prominent role in both formation and
correction of imbalances in acidbase metabolism.
Therapeutic effects
Given special importance as therapeutic agents but are also dangerous if improperly prescribed
and administered. Utilized for treatment of hypokalemia.
Uses
To prevent and treat potassium deficit secondary to diuretic or corticosteroid therapy. Also
indicated when potassium is depleted by severe vomiting, diarrhea; intestinal drainage, fistulas,
or malabsorption; prolonged diuresis, diabetic acidosis. Effective in the treatment of
hypokalemic alkalosis (chloride, not the gluconate).
Contraindications
Severe renal impairment; severe hemolytic reactions; untreated Addisons disease; crush
syndrome; early postoperative oliguria (except during GI drainage); adynamic ileus; acute
dehydration; heat cramps, hyperkalemia, patients receiving potassium-sparing diuretics, digitalis
intoxication with AV conduction disturbance.
Cautious use
Cardiac or kidney disease; systemic acidosis; slow-release potassium preparations in presence of
delayed GI transit or Meckels diverticulum; extensive tissue breakdown (such as severe burns);
pregnancy (category A); lactation.
Route & dosage
Hypokalemia
Adult: PO 10100 mEq/d in divided doses
IV 1040 mEq/h diluted to at least 1020 mEq/100 mL of solution (max: 200400 mEq/d,
monitor higher doses carefully)
Child: PO 13 mEq/kg/d in divided doses; sustained release tablets not recommended in
children
IV Up to 3 mEq/kg/24 h at a rate <0.02 mEq/kg/min
Administration
Oral
Give while patient is sitting up or standing (never in recumbent position) to prevent drug
induced esophagitis. Some patients find it difficult to swallow the large sized KCl tablet.
Do not crush or allow to chew any potassium salt tablets. Observe to make sure patient
does not suck tablet (oral ulcerations have been reported if tablet is allowed to dissolve in
mouth).
Swallow whole tablet with a large glass of water or fruit juice (if allowed) to wash drug
down and to start esophageal peristalsis.
Follow directions for diluting various liquid forms of KCl exactly. In general, dilute each
20 mEq potassium in at least 90 mL water or juice and allowed to completely before
administration.
Dilute liquid forms as directed before giving it through nasogastric tube.
Intravenous

PREPARE IV Infusion: Add desired amount to 1001000 mL IV solution (compatible with all
standard solutions). Usual maximum is 80 mEq/1000 mL, however, 40 mEq/L is preferred to
lessen irritation to veins. Note: NEVER add KCl to an IV bag/bottle which is hanging. After
adding KCl invert bag/bottle several times to ensure even distribution.
ADMINISTER IV Infusion: KCl is never given IV push or in concentrated amounts by any
route. Infuse at rate not to exceed 10 mEq/h. Adult patients with severe potassium depletion may
be able to tolerate 20 mEq/h. Too rapid infusion may cause fatal hyperkalemia.
Take extreme care to prevent extravasation and infiltration. At first sign, discontinue infusion
and select another site.
Incompatibilities Solution / Additive: Amphotericin B, dobutamine (potassium phosphate
only).Y-site: Amphotericin B cholesteryl complex, diazepam, ergotamine, methylprednisolone,
phenytoin, promethazine.

Adverse effects
GI:Nausea, vomiting, diarrhea, abdominal distension.
BodyWhole:Pain, mental confusion, irritability, listlessness, paresthesias of extremities, muscle
weakness and heaviness of limbs, difficulty in swallowing, flaccid paralysis.
Urogenital:Oliguria, anuria.
Hematologic:Hyperkalemia.
Respiratory:Respiratory distress.
CV:Hypotension, bradycardia; cardiac depression, arrhythmias, or arrest; altered sensitivity to
digitalis glycosides. ECG changes in hyperkalemia: Tenting (peaking) of T wave (especially in
right precordial leads), lowering of R with deepening of S waves and depression of RST;
prolonged P-R interval, widened QRS complex, decreased amplitude and disappearance of P
waves, prolonged Q-T interval, signs of right and left bundle block, deterioration of QRS contour
and finally ventricular fibrillation and death.
Monitor I&O ratio and pattern in patients receiving the parenteral drug. If oliguria occurs,
stop infusion promptly and notify physician.
Lab test: Frequent serum electrolytes are warranted.
Monitor for and report signs of GI ulceration (esophageal or epigastric pain or
hematemesis).
Monitor patients receiving parenteral potassium closely with cardiac monitor. Irregular
heartbeat is usually the earliest clinical indication of hyperkalemia.
Be alert for potassium intoxication (hyperkalemia, see S&S, Appendix F); may result
from any therapeutic dosage, and the patient may be asymptomatic.
The risk of hyperkalemia with potassium supplement increases (1) in older adults because
of decremental changes in kidney function associated with aging, (2) when dietary intake
of potassium suddenly increases, and (3) when kidney function is significantly
compromised.
Do not be alarmed when the tablet carcass appears in your stool. The sustained release
tablet (e.g., Slow-K) utilizes a wax matrix as carrier for KCl crystals that passes through
the digestive system.
Learn about sources of potassium with special reference to foods and OTC drugs.
Avoid licorice; large amounts can cause both hypokalemia and sodium retention.
Do not use any salt substitute unless it is specifically ordered by the physician. These
contain a substantial amount of potassium and electrolytes other than sodium.
Do not self-prescribe laxatives. Chronic laxative use has been associated with diarrhea
induced potassium loss.
Notify physician of persistent vomiting because losses of potassium can occur.
Report continuing signs of potassium deficit to physician: Weakness, fatigue, polyuria,
polydipsia.
Advise dentist or new physician that a potassium drug has been prescribed as long-term
maintenance therapy.
Do not open foil-wrapped powders and tablets before use.
Generic Name:Mannitol(mani-tole)
Brand Name:Osmitrol
Classifications:electrolytic and water balance agent; osmotic diuretic
Pregnancy Category:C
Availability
5%, 10%, 15%, 20%, 25% injectio
Actions
In large doses, increases rate of electrolyte excretion by the kidney, particularly sodium,
chloride, and potassium.
Therapeutic effects
Induces diuresis by raising osmotic pressure of glomerular filtrate, thereby inhibiting tubular
reabsorption of water and solutes. Reduces elevated intraocular and cerebrospinal pressures by
increasing plasma osmolality, thus inducing diffusion of water from these fluids back into
plasma and extravascular space.
Uses
To promote diuresis in prevention and treatment of oliguric phase of acute kidney failure
following cardiovascular surgery, severe traumatic injury, surgery in presence of severe jaundice,
hemolytic transfusion reaction. Also used to reduce elevated intraocular (IOP) and intracranial
pressure (ICP), to measure glomerular filtration rate (GFR), to promote excretion of toxic
substances, to relieve symptoms of pulmonary edema, and as irrigating solution in transurethral
prostatic reaction to minimize hemolytic effects of water. Commercially available in
combination with sorbitol for urogenital irrigation.
Contraindications
Anuria; marked pulmonary congestion or edema; severe CHF; metabolic edema; organic CNS
disease, intracranial bleeding; shock, severe dehydration, history of allergy; pregnancy (category
C), lactation; concomitantly with blood.
Route & dosage
Acute Kidney Failure
adult:IV Test Dose 0.2 g/kg or 12.5 g as a 15%20% solution over 35 min
Positive Response 3050 mL of urine over next 23 h, may repeat test dose 1 time. If still
negative, do not use.
Treatment 50100 g as 15%20% solution over 90 min to several hours
child: IV Test Dose 200 mg/kg (max: 12.5 g) over 35 min
Positive Response Urine flow of 1 mL/kg/h for 12 h
Maintenance 0.250.5 g/kg q46 h
Edema, Ascites
adult:IV 100 g as a 10%20% solution over 26 h
Elevated IOP or ICP
adult:IV 1.52 mg/kg as a 15%25% solution over 3060 min
Acute Chemical Toxicity
adult:IV 100200 g depending on urine output
Measurement of GFR
adult:IV 100 mL of 20% solution diluted with 180 mL NaCl injection infused at a rate of 20
mL/min

Administration
Intravenous

Note: Verify correct IV concentration and rate of infusion for administration to infants,
children with physician.
PREPARE IV Infusion: Give undiluted
ADMINISTER IV Infusion: Give a single dose over 3090 min. Oliguria: A test dose is given
to patients with marked oliguria to check adequacy of kidney function. Response is considered
satisfactory if urine flow of at least 3050 mL/h is produced over 23 h after drug
administration; then rate is adjusted to maintain urine flow at 3050 mL/h with a single dose
usually being infused over >=90 min. Concentrations higher than 15% have a greater tendency to
crystallize. Use an administration set with an in-line IV filter when infusing concentrations of
15% or above.
Incompatibilities Solution / Additive: Imipenem-cilastatin. Y-site: Cefepime, doxorubicin
liposome, filgrastim.
Store at 1530 C (5986 F) unless otherwise directed. Avoid freezing.

Take care to avoid extravasation. Observe injection site for signs of inflammation or
edema.
Lab tests: Monitor closely serum and urine electrolytes and kidney function during
therapy.
Measure I&O accurately and record to achieve proper fluid balance.
Monitor vital signs closely. Report significant changes in BP and signs of CHF.
Monitor for possible indications of fluid and electrolyte imbalance (e.g., thirst, muscle
cramps or weakness, paresthesias, and signs of CHF).
Be alert to the possibility that a rebound increase in ICP sometimes occurs about 12 h
after drug administration. Patient may complain of headache or confusion.
Take accurate daily weight.
Report any of the following: Thirst, muscle cramps or weakness, paresthesia, dyspnea, or
headache.
Family members should immediately report any evidence of confusion.
Do not breast feed while using this drug.
Generic Name:Albuterol
Brandname:Accuneb, Novosalmol , Proventil,Proventil HFA,Proventil Repetabs, Salbutamol,
Ventolin, Ventolin Rotocaps, Volmax
Classifications: autonomic nervous system agent; beta-adrenergic agonist
(sympathomimetic); bronchodilator (respiratory smooth muscle relaxant)
Prototype: Albuterol
Pregnancy Category: C

Availability:
2 mg, 4 mg tablets; 4 mg, 8 mg extended release tablets; 2 mg/5 mL syrup; 200 mcg capsules
for inhalation; 0.083%, 0.5% solution for inhalation.
Actions:
Synthetic sympathomimetic amine and moderately selective beta2-adrenergic agonist with
comparatively long action. Acts more prominently on beta2 receptors (particularly smooth
muscles of bronchi, uterus, and vascular supply to skeletal muscles) than on beta1 (heart)
receptors. Minimal or no effect on alpha-adrenergic receptors. Inhibits histamine release by mast
cells.
Therapeutic effects:
Produces bronchodilation, regardless of administration route, by relaxing smooth muscles of
bronchial tree. This decreases airway resistance, facilitates mucus drainage, and increases vital
capacity.
Uses:
To relieve bronchospasm associated with acute or chronic asthma, bronchitis, or other reversible
obstructive airway diseases. Also used to prevent exercise-induced bronchospasm.
Route & Dosage
Bronchospasm
adult: PO 24 mg 34 times/d, 48 mg sustained release 2 times/d Inhaled 12 inhalations
q46h
child: PO 26 y, 0.10.2 mg/kg t.i.d. (max: 4 mg/dose); 612 y, 2 mg 34 times/d; Inhaled6
12 y, 12 inhalations q46h
Administration
Oral
Do not crush extended release tablets. Scored tablets may be broken in half.
Note: An initial dose of 2 mg t.i.d. or q.i.d. is recommended for older adult patients.
Store tablets and syrup between 225 C (3677 F) in tight, lightresistant container.
Inhalation
Administer albuterol 2030 min before concomitant beclomethasone (Vanceril)
inhalation treatments to allow deeper penetration of beclomethasone into lungs, unless
otherwise directed by physician.
Store canisters between 1530 C (5986 F) away from heat and direct sunlight.
Adverse effects
BodyWhole: Hypersensitivity reaction.
CNS: Tremor, anxiety, nervousness, restlessness , convulsions , weakness , headache,
hallucinations. CV: Palpitation, hypertension, hypotension, bradycardia, reflex tachycardia.
SpecSenses:Blurred vision, dilated pupils.
GI: Nausea, vomiting.
other: Muscle cramps, hoarseness.
Diagnostic Test Interference Transient small increases in plasma glucose may occur.
interaction
drug: With epinephrine, other sympathomimetic bronchodilators, possible additive effects; mao
inhibitors, tricyclic antidepressants potentiate action on vascular system; beta-adrenergic
blockers antagonize the effects of both drugs.

Monitor therapeutic effectiveness which is indicated by significant subjective
improvement in pulmonary function within 6090 min after drug administration.
Monitor for: S&S of fine tremor in fingers, which may interfere with precision handwork;
CNS stimulation, particularly in children 26 y,
Lab tests: Periodic ABGs, pulmonary functions, and pulse oximetry.
Consult physician about giving last albuterol dose several hours before bedtime, if drug-
induced insomnia is a problem.
Review directions for correct use of medication and inhaler.
Avoid contact of inhalation drug with eyes.
Do not increase number or frequency of inhalations without advice of physician.
Notify physician if albuterol fails to provide relief because this can signify worsening of
pulmonary function and a reevaluation of condition/therapy may be indicated.
Note: Albuterol can cause dizziness or vertigo, take necessary precautions.
Do not use OTC drugs without physician approval. Many medications (e.g., cold
remedies) contain drugs that may intensify albuterol action.
Do not breast feed while taking this drug without consulting physician

Drug Name

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Drug Name

Uploaded by

Copyright:

Available Formats

Drug Name

Generic Name : metoprolol , metoprolol succinate , metoprolol tartrate

You might also like